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Abstract
The physics of protons makes them well-suited to conformal radiotherapy due to the
well-known Bragg peak effect. From a proton’s inherent stopping power, uncertainty
effects can cause a small amount of dose to overflow to an organ at risk (OAR). Previous
models for calculating normal tissue complication probabilities (NTCPs) relied on the
equivalent uniform dose model (EUD), in which the organ was split into 1/3, 2/3 or
whole organ irradiation. However, the problem of dealing with volumes <1/3 of the to-
tal volume renders this EUD based approach no longer applicable. In this work the case
for an experimental data-based replacement at low volumes is investigated. Lung fibro-
sis is investigated as an NTCP effect typically arising from dose overflow from tumour
irradiation at the spinal base. Considering a 3D geometrical model of the lungs, irra-
diations are modelled with variable parameters of dose overflow. To calculate NTCPs
without the EUD model, experimental data is used from the quantitative analysis of
normal tissue effects in the clinic (QUANTEC) data. Additional side projects are also
investigated, introduced and explained at various points. A typical radiotherapy course
for the patient of 30×2Gy per fraction is simulated. A range of geometry of the target
volume and irradiation types is investigated. Investigations with X-rays found the ma-
jority of the data point ratios (ratio of EUD values found from calculation based and
data based methods) at ∼20% within unity showing a relatively close agreement. The
ratios have not systematically preferred one particular type of predictive method. No
Vx metric was found to consistently outperform another. In certain cases there is a good
agreement and not in other cases which can be found predicted in the literature. The
overall results leads to conclusion that there is no reason to discount the use of the data
based predictive method particularly, as a low volume replacement predictive method.
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Chapter 1
Introduction and Overview
1.1 Thesis Outline
Since its beginnings in the middle of the 20th century, proton therapy is an almost
exponentially growing field (Sisterson et al., 2004) and presently there are plans
well underway to complete the construction of two new proton therapy centres
in the UK at Christie Hospital, Manchester and UCLH in London. Globally, this
continued almost exponential increase in number of treatment centres and numbers
of patients treated per year means the consideration of negative effects to patients
from proton beam models is of increasing importance. The equivalent uniform
dose (EUD) model that is used to calculate normal tissue complication probabilities
(NTCPs) is currently too simplistic because it is based on large irradiated volumes,
typically at least one third of an organ (Niemierko, 1997). For proton beams which
have a large fall-off dose gradient at the end of the spread out Bragg peak (SOBP)
(Bortfeld, 1997), this problem of small volumes required for the calculation of
NTCP becomes particularly important. Given the sharp fall-off dose gradient in
14
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proton therapy, it is much more likely that only a very small fraction of OAR (organ
at risk) is irradiated and hence the large volume assumption used in the EUD so
far is no longer a good approximation (Emami, 1991). The depth dose curve for
X-rays deposits dose continuously through the patient very differently to proton
depth dose curves which exhibit the classical Bragg peak and practically no dose
thereafter (ICRU report 49, 1993, Berger et al., 1993). Therefore investigating a
replacement calculation model is an important area in modern research. This work
takes the clinical example of lung fibrosis (the formation of excessive connective
tissue in the lung causing the patient to have difficulty breathing and likely die
within 2-5 years) as an NTCP effect which can typically arise from small-volume
dose overflow from irradiation of tumours at the base of the spine due to inherent
uncertainties in planning and delivery of proton therapy. An experimental data-
based interpolation method at low organ volumes could also prove useful for other
proton therapy treatment cases where the EUD method may not be applicable.
Therefore this work has potential other applications, as well for wider proton
therapy, if the data-based calculation method makes valid predictions at the low
volume scale and agrees with the EUD calculation model when the volume is scaled
up to regions where the EUD model is applicable and valid.
This work will investigate the case for an experimental data-based replacement
at low volumes and by matching this to large volumes with the old EUD approach,
limitations of this data-based method might be expected to be discerned. A ge-
ometrical approach is adopted as influenced by the paper by Rutkowska et al.,
2012. Spread out Bragg peaks of physical dose will be modified to include bi-
ologically effective dose depth by use of a sophisticated analytical linear energy
transfer-relative biological effect (LET-RBE) model in the simulations. As the
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beam travels through the simulated 3D lung volume it will spread by means of
a double Gaussian. The proton beam irradiations will be modelled with variable
parameters in order to simulate various possible scenarios of dose overflow into
the lung. In the model there is also included an EUD-based NTCP calculator and
parameterisations for full variability and comparison with the existing method-
ology based on work by Gay et al., 2007. My project will also include a side
project of varying largely uncertain input parameters for the relative biological
effect (RBE) model parameters in the code to determine relations between RBE
and NTCP based on the EUD model. This will be done based on experimental
data given on the referenced parameters in work by Wilkens et al., 2004 and the
sub-references within and will be discussed in more detail in chapter 4. A modular
structure of programming will be presented in chapter 5 and the location and dis-
cussion of each of the modules within this report will be presented to achieve the
overall working modules. In order to calculate NTCPs without the EUD model,
experimental data is used from the quantitative analysis of normal tissue effects
in the clinic (QUANTEC) data to match the resulting Vx% value (the volume of
the organ that receives at least x Gy, in %) to a probability of induction of lung
fibrosis across all fractions of treatment (Bentzen et al., 2010). The EUD calcula-
tions are performed using both parameter values from the original Emami study
(Emami et al., 1991) and the more modern values from the Marks study (Marks
et al., 2010) for comparison with the interpolated data from the QUANTEC study
which was gathered using X-ray data. In addition, studies with X-ray simulations
and step-functions to spread the proton beam are performed and the calculations
are compared with the interpolated data predictions.
The main idea for this project is to compare the results between the EUD model
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and the predictions made from the data based QUANTEC model to investigate
the case for the EUD replacement for low volumes in proton therapy. While
the individual proton Bragg peaks are computed analytically (Bortfeld, 1997),
the individual optimised weighting factors for construction of the overall spread
out Bragg peaks are determined by a novel optimisation method developed in
this project, with references to other work where applicable. Further, developed
uniquely within this project, an automated analytical linear energy transfer (LET)
depth has, to my knowledge, not been computed before. The method of linearly
interpolating the function space for the parabolic cylinder functions (see Appendix
F) - the LET interpolation can also be performed in a non-linear way and this was
investigated as well within this project. The LET effects are computed analytically
originally based on work by Wilkens et al, 2003, and analytical RBE effects are
determined directly based on work by Wilkens et al, 2004. As will be discussed
in more detail in chapter 4, the impact of variable RBE effects on NTCP values
for given simulated setups based on the model input experimental uncertainties
using the EUD model in one dimension with two sets of parameters, is also a novel
investigation within this project.
This project is entirely simulation based and therefore computational. How-
ever, the models used contain experimental results within their appropriate sources.
The project research goals can be summarised as follows: How well does a geo-
metrical model, as designed in this project, fit a true picture of the human lungs?
This question is investigated in Appendix D. How to use a SOBP mechanism for
the model? This question is investigated in section 2.3. How to construct a lung
volume for simulation with appropriate dimensions? This question is investigated
in section 5.2. How to implement appropriate beam spread functions, taking into
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account pencil beams for proton therapy? This question is investigated in section
5.3. How well does a data based replacement agree with the EUD model at large
volumes and can the data based approach therefore be used to make predictions
where the EUD model is no longer valid at < 1/3 of the total organ volume or
< 10% where there is no experimental data, and how accurate do we expect these
predictions to be? This question is investigated in chapter 6. How sensitive are the
models to small changes in input variables? This question is investigated in section
6.1. Can we validate the models? This question is investigated in Appendix E.
How to calculate the errors on these predictions, how to design an interpolation
mechanism for the QUANTEC data, and how meaningful are the different types
of interpolation which can be used? These questions are investigated in section
6.2. How to simulate X-ray irradiations along with the proton beam based simu-
lations? This question is investigated in section 2.4. Where X-ray irradiations are
modelled instead of proton beams how does this influence the results (of varying
proton beam setup configurations)? This question is investigated in section 6.3.3.
Chapter 2 will discuss the associated theory of ionising dose deposition which is
relevant for this work. Chapter 3 will review the relevant literature for mathemat-
ical models which describe biological effect on normal and cancerous tissue in the
lung for this project. Chapter 4 will focus on relative biological effect modelling
for protons. Chapter 5 will focus on the methodology of setting up the appropriate
simulations for the main part of this project. Chapter 6 will provide the results
which have been achieved in the different simulated scenarios along with relevant
discussions. Chapter 7 will provide the conclusions and summary of the project.
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1.2 Overview of Proton Therapy
1.2.1 Introduction to Proton Therapy
The origins of the field of proton therapy are usually cited back to the seminal
paper by Robert Wilson, 1946 “Radiological use of fast protons”. The first medical
use was thereafter in 1954 at Lawrence Berkeley National Laboratory (Sisterson et
al., 2004). Proton therapy is irradiation of cancer tissue using protons as a form
of radiotherapy. The goal is to completely destroy every cancer cell while sparing
the normal healthy tissue from irradiation as much as possible. As with conven-
tional radiotherapy, the patient does not receive all of the dose in one treatment.
Instead, the overall treatment is fractionated, whereby the patient receives single
fractions at a time, typically once a day, due to the biological advantages gained
(the ‘R’s of radiotherapy - repair, redistribution, reoxygenation, repopulation and
radiosensitivity). For a single fraction of treatment, typically a number of different
fields1 are used (usually 3-5) to create an overall plan. These fields are delivered
through the positioning of the patient onto a movable treatment table in addition
to the gantry which surrounds the table and rotates, from which the proton source
is delivered to the patient as shown in Figure 1.1. In proton therapy, dose is always
defined in units of Gy which is Joules per kg.
1.2.2 Why Protons?
A proton is a strongly interacting positively charged subatomic particle composed
of three quarks. The physical characteristics of protons over conventional pho-
ton irradiation show advantageous properties exhibited due to the well defined
1Respective directions from which the beam used for treatment are coming from.
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Figure 1.1: Graphical display of table and gantry used in proton therapy (Pedroni,
E et al., 2001).
range and highly concentrated dose volume region: the Bragg peak (Paganetti et
al., 2005). Although proton interactions with matter are complicated, only the
Coulomb interactions are relevant for the purpose of proton therapy.
The width of the Bragg peak requires modulation to produce a clinically useful
field for irradiation of arbitrarily large tumour volumes along, and orthogonal, to
the beam; this is achieved using a number of range adjusted and appropriately
fluence weighted Bragg peaks, to produce a clinically useful region of uniform dose
- the spread out Bragg peak displayed on the red line in Figure 1.2. Thus the
clinical rationale for proton therapy is derived from the feasibility of a relatively
1.2. OVERVIEW OF PROTON THERAPY 21
higher dose delivery to the tumour and hence an increased tumour control prob-
ability (TCP) (Niemierko et al., 1992). The high degree of conformity and steep
dose gradients lead to substantial normal tissue sparing; these advantages (over
conventional X-ray radiotherapy) have been demonstrated based on NTCP and
TCP calculations for esophageal cancer (Isacsson et al., 1998), locally advanced
rectal cancer (Isacsson et al., 1996) and paraspinal tumours (Isacsson et al., 1997).
Figure 1.2: Depth-dose characteristics of photon and proton irradiation (Levin et al.,
2005). The advantageous well-defined region of dose deposition for protons is shown in
the Bragg peak here at ∼150mm.
1.2.3 What is Lung Fibrosis?
Patients who receive radiation therapy are at risk of radiation pneumonitis (also
referred to as lung fibrosis, lung pneumonitis, pulmonary fibrosis), a potentially
serious inflammatory and sometimes fatal condition (Tucker et al., 2012). Pul-
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monary fibrosis is the formation or development of excess fibrous connective tissue
(fibrosis) in the lungs. It is also described as “scarring of the lung”. It is one of the
restrictive conditions of human respiratory disorders. Pulmonary fibrosis can lead
to other medical problems, including collapsed lung, lung infections, blood clots
in the lungs and lung cancer. As the disease gets worse, it can lead to respira-
tory failure, pulmonary hypertension and heart failure. A person with pulmonary
fibrosis may need supplemental oxygen to help with breathing. When it does de-
velop, radiation induced lung fibrosis usually develops within 6-12 months after
completion of radiation therapy and can progress for up to 2 years before stability
occurs (Evans et al., 1925), (Roswit et al., 1977).
Matsuo et al., 2012 state that radiation pneumonitis (RP) is one of the most
common toxicities after SBRT2, as well as after conventional radiotherapy to the
lung. The reported rates of symptomatic RP after SBRT range from 9 to 28%
(Yamashita et al, 2007, Ricardi et al, 2009, Borst et al, 2009, Guckenberger et
al, 2010, Ong et al, 2010, Barriger et al, 2012, Stauder et al, 2011). Matsuo et
al., 2012, also state that it is very important to develop a method to predict the
risk of RP after SBRT for the lung. Appelt et al., 2014 state that understanding
the dose-response of normal tissue is of critical importance for the optimization
of radiotherapy (RT). Further, that RP remains a dose-limiting toxicity in the
treatment of lung cancer patients, and hence identification of relationships between
dose and the probability of RP is vital if constraints on the safely deliverable
radiation dose are to be determined.
2Sterotactic Body Radiation Therapy, an X-ray radiation therapy approach which delivers
high dose radiation to a target within the body from many directions, either in a single fraction
or up to eight treatment fractions.
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Figure 1.3: Figure a shows the CT (computed tomography) scan obtained 4 months
after completion of radiotherapy, and figure b shows the CT scan obtained 26
months after the completion of radiotherapy showing lung fibrosis in the lung
tissue adjacent to the treated chest wall region (Choi et al., 2004).
1.2.4 The Importance of Uncertainties
Since geometrical misses of the proton pencil beams can result in failure to erad-
icate the tumour and additional unwanted dose to the OARs, setup accuracy is
thus very important (Bel et al., 1996). In practice, there will always be sources of
uncertainty, which need to be accounted for accordingly, taken into account in the
form of safety margins. The gross tumour volume (GTV) defines the macroscopic
visible tumour, subsequently the clinical tumour volume (CTV) is defined by the
oncologist to include the estimated local microscopic invasions of the tumour, taken
into account by an extension around the GTV. The 3D spatial uncertainties cur-
rently in the form of setup, translational and range are estimated and the CTV
is extended with a safety margin which forms the planning target volume (PTV).
The treatment plan is designed according to the PTV such that the high dose
region matches the PTV as closely as possible (e.g. a 95% isodose surface - where
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the volume receives at least 95% of the prescribed dose).
Figure 1.4 serves to graphically illustrate the concept of a small volume irra-
diation to potentially <1/3 of the total organ volume due to dose overflow to the
lung from the original treatment to a tumour on the base of the spine. This is
as an unwanted result of uncertainties in the planning and delivery of this proton
therapy treatment and leads to the potential for induction of lung fibrosis.
Figure 1.4: Example of dose overflow into the lung due to inherent uncertainties in
treatment (Clements, 2012). The greyscale image shows the original CT image of the
lungs and the surrounding tissue and the coloured region shows the dose overlay for this
CT slice.
1.2.5 Modern Techniques in Proton Therapy
Passive Scattering
The proton beam broadening required for passive scattering, the technique used
in the first proton treatments (and still used today in the treatment of close range
tumours e.g. the OPTIS facility at PSI, Switzerland), is achieved in the beam
direction from the uniform dose profile through the use of range adjusted and
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Figure 1.5: Passive scattering is one possibility of conforming the beam shape to the
tumour (Koehler et al., 1975).
weighted Bragg peaks to produce the SOBP. In the orthogonal direction, the nar-
row pencil beam is broadened by the use of scattering foils along the beam direction
(Koehler et al., 1975), as shown in Figure 1.5. The beam is effectively spread in
the orthogonal direction to the beam where the amount of scattering depends
on the atomic number of the material used. A large scattering can therefore be
achieved through the use of high-Z foils directly inserted in the beam. As shown
in the figure, patient and field-specific collimators are used to conform the shape
of the field to the cross-sectional shape of the target volume, in addition to the
use of compensators to match the distal end of the SOBP to the distal end of the
tumour; in this way the resulting delivered fields are shaped to better conform the
delivered dose to the tumour.
Active Scanning
New techniques further to passive scattering have since been developed including
active scanning as used in Intensity Modulated Proton Therapy (IMPT). First
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Figure 1.6: In active scanning the beam is spread laterally using magnetic fields to steer
the protons, scanned across the tumour using a scanning magnet (Kanai et al., 1980).
suggested by Kanai et al. (Kanai et al., 1980), the principle of active scanning is
to steer the protons using magnetic fields in order to spread the beam laterally
as shown in Figure 1.6. In contrast to passive scattering the beam is not broad-
ened through scattering but is instead scanned across the tumour volume using a
scanning magnet. Thus to achieve the variation orthogonally and along the beam
direction, a combination of energy variation and beam steering is used. Optimisa-
tion of the individual fluences for each pencil beam is then performed to produce
the required dose uniformity across all of the spots (Albertini et al., 2009). For
active scanning, there is no requirement for the use of collimators and compen-
sators as with the passive scattering technique and it can be fully automated and
computer controlled. In order to achieve a given total dose to the target volume,
fewer protons need to be delivered to the patient and thus active scanning is more
efficient than passive scattering in that it achieves a lower dose to the surrounding
healthy tissue.
Chapter 2
Theory: Calculating/Estimating
Ionising Dose Deposition for
Therapy
This chapter includes the relevant theory for the construction of a single proton
Bragg peak, in particular the Bortfeld model, spread out Bragg peaks project (the
method of moving from a single proton Bragg peak to what is used clinically,
which is a set of fluence and energy weighted Bragg peaks to form a clinically
useful region), and X-ray depth dose theory (which is also useful for modelling
X-rays in the simulated lung volume). The Bethe Bloch formula while relevant to
protons at this energy level (typically less than 500MeV in clinical proton therapy)
is contained in the Appendix A.
Other areas of theoretical discussion which are relevant for this project are
covered elsewhere in this thesis; this includes modelling proton relative biological
effect, the theory of which is covered in chapter 4, modelling normal tissue compli-
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cation probability, the theory of which is covered in chapter 3, and proton linear
energy transfer, the theory of which is not included in the main part of the thesis
but can be found in Appendix F.
A model of the proton beam is required and gives the main focus of this chapter
because one of the main aims is to investigate the effects on variable proton beam
overflows to a simulated 3D lung volume, in order to compare calculated EUD
values with EUD values which correspond to data interpolated from the QUAN-
TEC study which will be discussed in chapter 3. Consideration of the initially
1D beam will also be useful in other areas of this project including SOBP flatness
investigation and optimisation method, and study of variations of uncertainties on
RBE input parameters and the resulting effects on NTCP within the EUD model,
which will be discussed later in this thesis.
2.1 CSDA - Continuous Slowing Down Approx-
imation
The CSDA (as contained in Bortfeld 1997) is the simplest method I have found to
model the slowing down of protons for use in models for proton therapy. It is worth
noting that the Bethe Bloch model (see Appendix A) stays within the continuous
slowing down approximation for protons. I have not included the Bethe Bloch
discussion in the main body of the text because, while it is relevant for proton
dose deposition, it is not used in the main part of this project. In R.Wilson’s
original 1946 paper “On the radiological use of fast protons” he uses Geiger’s rule
(published in Evans, R.D., 1955):
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R0 = αE
p
0 (2.1)
In Eq. (2.1) the range R0 is given by a power dependence on the energy E0 where
p and α are constants. In Wilson’s paper the author recommends to use a value
of p = 1.5; this has since been updated in ICRU 49, where it is recommended to
use a value of p = 1.77. The Bragg-Kleeman rule describes the α constant:
α =
c
√
Aeff
ρ
(2.2)
Where c is a constant between different materials, Aeff is the effective atomic
mass of the absorbing medium and ρ is the density of the absorbing medium.
From Geiger’s rule in Eq. (2.1), the proton travels to max range R0 at initial
energy E0. Therefore at energy along the z (direction of travel) E (z) the proton
will travel R0 − z:
R0 − z = αE (z)p (2.3)
The CSDA stopping power simply derives directly from this:
E (z) =
1
α1/p
(R0 − z)1/p (2.4)
∴ −∂E(z)
∂z
=
1
pα1/p
(R0 − z)1/p−1 (2.5)
There is an asymptote at z = R0 for
∂E
∂z
(the maximum range of the proton in this
approximation).
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2.2 The Bortfeld Model
The Bortfeld model is built on the CSDA, with some additional considerations
which are not considered in the Bethe Bloch model. In various cases it is desirable
to have an analytical representation of the Bragg curve, rather than using mea-
sured or numerically calculated data. Bortfeld’s 1997 paper provides an analytical
approximation of the Bragg curve in closed form. The validity of the underly-
ing model is for proton energies between about 10 and 200 MeV. As stated in
the paper, the main four constituents of this model are: a power-law relationship
describing the range-energy dependency, a linear model for the fluence reduction
due to Coulombic nuclear interactions, assuming local deposition of a fraction of
the released energy, a Gaussian approximation of the range straggling distribu-
tion, and a representation of the energy spectrum of poly-energetic beams by a
Gaussian with a linear “tail”.
2.2.1 Depth Dose Without Range Straggling Effects
The energy fluence Ψ (z) at depth z is given by the particle fluence Φ, which is the
number of particles per cm2 and the energy E (z), which is the energy remaining
for 1 particle at depth z.
Ψ (z) = Φ (z)E (z) (2.6)
The total energy released per unit mass (definition) is given by the TERMA T ,
where ρ is the mass density of the absorbing medium:
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T (z) = −1
ρ
∂Φ(z)
∂z
(2.7)
From Eqs. (2.6, 2.7):
T (z) = −1
ρ
(
Φ (z)
∂E(z)
∂z
+ E(z)
∂Φ(z)
∂z
)
(2.8)
The first term in Eq. (2.8) corresponds to energy reduction of protons in matter
mainly transferred to electrons via the Coulomb interaction. These electrons have
negligible range (tens of µm) due to the fact only a small amount of energy is
transferred to each electron; this is due to the small ratio of the electron to pro-
ton mass. This term directly corresponds to a dose delivered. The second term
corresponds to a reduction in number of protons (due to non elastic nuclear inter-
actions). These nuclear interactions release energy. In Bortfeld’s model, a certain
fraction of this energy γ is assumed to be absorbed locally, ignoring the rest. It is
stated that for simplicity in Bortfeld’s model it is assumed γ = 0.6. Therefore the
total absorbed dose is given by:
Dˆ (z) = −1
ρ
(
Φ (z)
∂E(z)
∂z
+ γE(z)
∂Φ(z)
∂z
)
(2.9)
Eq. (2.9) is a depth dose curve, and in order to determine it, the only knowledge
needed are the E(z) and Φ(z) functional relations respectively (hence their differ-
ential forms with respect to z). These are obtained from the known energy range
and the probability of non elastic nuclear interactions respectively. For the E(z)
term, the result directly from the CSDA in Eq. (2.4) and the derivative of this in
Eq. (2.5) can be used.
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The following section describes the Φ(z) term. As stated in Bortfeld’s model,
for energies above ∼20MeV, protons are lost from the beam by a non-negligible
probability (fluence term) due to non-elastic nuclear interactions. As discussed in
the paper, this probability P as a function of range has been tabulated by Janni
Lee et al., 1982 and those authors have derived the proportionality:
Φ(z) =
1
1− P (R0 − z) (2.10)
It is stated that while the data can be fitted using a power law approximation as
shown in Eq. (2.11), for simplicity a straight line can be used. This is the fit that
Bortfeld uses in the model, given in Eq. (2.12) where β ≈ 0.012cm−1.
Φ(z) ∝ 1 + 0.018 (R0 − z)0.87 (2.11)
Φ(z) ∝ 1 + β (R0 − z) (2.12)
Normalising to the ‘primary’ fluence (fluence at z = 0) gives the equation:
Φ(z) = Φ0
1 + β (R0 − z)
1 + βR0
(2.13)
⇒ −∂Φ(z)
∂z
= −Φ0 ∂
∂z
(
1− β
1 + βR0
z
)
= Φ0
β
1 + βR0
(2.14)
Therefore up to this point all the results which are needed for the proton depth
dose distribution without range straggling are acquired. To go from this point to
the final result for the proton depth dose distribution without range straggling,
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the methodology is contained in Appendix B. The final result for the depth dose
formulation without consideration of range straggling effects of protons is:
Dˆ(z) = Φ0
(R0 − z)1/p−1 + β (1 + pγ) (R0 − z)1/p
ρ (1 + βR0) pα1/p
(2.15)
Eq. 2.15 is valid for z < R0. For z > R0, Dˆ(z) = 0. The symbols used in this
equation are as defined in this chapter. Eq. (2.15) can be written as the sum of
two contribution terms:
Dˆ(z) = Dˆ1(z) + Dˆ2(z) = a1 (R0 − z)1/p−1 + a2 (R0 − z)1/p (2.16)
The first term Dˆ1(z) is the dose contribution from protons with no nuclear in-
teractions; there is a neglection of range straggling at this stage, so there is an
asymptote at z = R0 causing an unrealistically sharp peak. The term is propor-
tional to the stopping power. The second term Dˆ2(z) represents the dose delivered
by the relatively small fraction of protons that have nuclear interactions. It de-
creases with z and is zero at z = R0. Dˆ2(z) comprises the dose resulting not only
from nuclear interactions but also the non-nuclear interactions that take place
before the nuclear collision1.
2.2.2 Depth Dose With Range Straggling Effects
In this section, a monoenergetic beam is assumed at this stage and for the first
part, considering the protons which have no nuclear interactions as described by
the Dˆ1(z) term in Eq. 2.16. For an individual proton with energy E0, the range R0
1Note on units: ρ in g/cm3 → Dˆ in MeV/g. Multiplying this by 109e/C=1.602×1010 for Dˆ
in Gy
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should be Gaussian distributed (from statistics) and although the real distribution
is slightly asymmetric, this is in fact a good approximation (Bortfeld, 1997). Simi-
larly, the range z where the protons have lost part of their energy E0−∆E = E(z)
is Gaussian distributed as before, about the mean value. The mean depth is given
by:
z¯(E0,∆E) (2.17)
With a standard deviation of σz(z¯), where the width of the distribution depends
on the mean depth. Therefore there is an uncertainty at the depth z for an energy
of E(z) which gives rise to depth straggling. Furthermore, one can consider the
same phenomenon from the reversed perspective, for a given knowledge of the
depth z, due to exactly the same statistical effects, there will be an uncertainty in
E(z), the remaining energy, which will be Gaussian distributed. From the known
general form of the Gaussian distribution, the Gaussian distribution for depth for
a given energy remaining, distributed about z¯ is:
1
σz(z¯)
√
2pi
e
− (z−z¯)2
2σz(z¯)2 (2.18)
The remaining energy at depth z gives the stopping power and dose deposited from
Dˆ1 (due to the β dependence). So the next step is to write the individual dose
contribution terms as featured in Eq. (2.16) including the effects of this Gaussian
distribution to model range straggling. See Appendix B for the missing steps. The
final result for depth dose with consideration of the range straggling effects is:
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D(z) =
Φ0e
ζ2
4 σ
1
pΓ
(
1
p
)
√
2piρ(1 + βR0)pα
1
p
[
1
σ
D(p)− 1
p
(−ζ) + β(1
p
+ γ)D(p)− 1
p
−1(−ζ)
]
(2.19)
There are a number of “special functions” which appear in Eq.(2.19) which have
not yet been defined in this chapter - I have included an appendix describing these
functions, see Appendix B. Briefly listing these, they are of the form “parabolic
cylinder functions” D(p)ν which are formally defined as in Appendix B as solutions
to the Weber differential equation. Γ(z) is the Gamma function which is given
by Euler’s formulation and the Lanczos approximation as in the same appendix.
In Eq.(2.19), the Gaussian distribution has been approximated about the mean
depth z¯(E,∆E) with the standard deviation of σz(z¯) by setting σz(z¯) = σ, with
a minimum at z = 0 and a maximum at z = R0. The value of σ for an initially
monoenergetic beam depends on the range R0 (or equivalently, E0). The functional
relation can be approximated by (the α term definition can be found in the CSDA
section of this chapter):
σ2 ≈ α′ p
3α
2
p
3p− 2R
3− 2
p
0 (2.20)
Where α′ is a factor that as with α depends on the stopping matter. For water
we obtain: α′ ≈0.0087MeV2/cm. Inputting the relevant values for water into Eq.
(2.20):
σ ≈ 0.012R0.9350 (2.21)
R0 and σ are in cm. Because the power term is approximately 1, this means that
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σ is approximately proportional to R0 with a value of approximately 1% of R0.
Therefore as an example, 150 MeV protons have a range of R0 = 15.635cm and
have a spread in z of σ =0.16cm due to range straggling.
Figure 2.1: Example output (150MeV) of my Bortfeld Bragg peak simulations.
At this point, the beam has been assumed to be monoenergetic. As is stated in
the Bortfeld 1997 paper, this is not truly the case and modification to the formula
used is needed. Therefore the boxed formula for D(z) as in Eq. (2.19) needs
additional considerations to arrive at the final result used in the paper, namely
the outcomes that result from polyenergetic considerations - that the beam is not
truly monoenergetic, and a representation of the energy spectrum of poly-energetic
beams by a Gaussian with a linear “tail”. At this point I invite the reader to
consider Appendix B where I have outlined the steps involved in order to arrive
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at the updated expression for D(z) taking into account these considerations and
critical for plotting the analytical depth dose curve for use in my simulations where
I am including all of these effects.
2.3 Spread Out Bragg Peaks (SOBPs)
For use in the intended simulations in this project, the use of a SOBP optimiser
was needed in order to produce proton beams with a clinically useful width (most
tumours are typically much wider than the width of a single proton Bragg peak so
modulation is required with multiple energy and fluence weighted Bragg peaks).
Furthermore in doing so, a side part of this project was realised in order to pro-
duce very flat regions as a result of the optimisation program. In this part of the
project, a novel method for optimising SOBPs was investigated and here is pre-
sented as a first-pass look at a ‘genetic’2 based approach to SOBP optimisation.
At present, the best flatness achieved in the literature is 1.5%-2% and these will be
presented in this section. The method used here has achieved flatnesses of 0.1%, an
improvement more than a factor of 10. However the price to pay for such flatness
is a more complex optimisation procedure, inherently longer computational times,
and the need to define the limits accurately in z (the direction of the beam) in 1
dimension.
2A genetic algorithm (GA) is a method for solving both constrained and unconstrained
optimization problems based on a natural selection process that mimics biological evolu-
tion. The algorithm repeatedly modifies a population of individual solutions. Source:
http://mathworks.co.uk
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2.3.1 Introduction
Here, firstly a literature review of present methods for achieving SOBP flatness
and the flatnesses these methods can achieve will be presented. Having flatter
physical dose SOBPs is beneficial for proton therapy. The principle of the method
used in my computational program is to use a Monte Carlo based approach and
‘evolve’ the solutions to the ‘genetically’ optimal configuration for the weighting
functions for the Bragg peaks. The principles of how this program works, the
results it has achieved, a discussion of the methodology, and any conclusions that
can be drawn will be presented.
Nie et al., 2009, quote that the best SOBP flatness in publications is 1.5%.
Herault et al., 2007, record the SOBPs are reproduced with deviations inferior
to 3%, if one limits oneself to collimator sizes used for clinical situations, i.e.,
larger than 7.5mm. Zheng et al., 2009, use an existing code package to model the
proton therapy unit and simulate beam profiles. The authors state that SOBPs
were simulated by combining the simulation results for various steps of the range
modulator wheel. Simulations were performed in a water phantom as well as
in air. Up to 108 proton histories were tracked per simulation to achieve < 2%
flatness. Hsiao-Ming Lu and Hanne Kooy, 2006, developed a new method for the
optimization of the current modulation function used in passive scattering systems
for proton therapy. They state that differences in the uniformity are negligible
< 1% for most of the useful modulation widths, and are noticeable only for small
modulation widths used to cover small target volumes mostly seen in radiosurgery
treatments.
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2.3.2 Methodology
Figure 2.2: A visual representation of how the optimisation converges on the best
solution (minimizing χ2). The W∆(R) values are the respective weighting factors
for the individual Bragg peaks and the plotted crosses × indicate example Monte
Carlo based sets of data generated before the flatness evaluator is computed.
The single Bragg peaks which make up the overall SOBP are used as per
the Bortfeld Model (Bortfeld, 1997). The method used to compute the parabolic
cylinder functions in D is readily implemented using the NIST algorithm formula-
tion (National Institute of Standards and Technology). Originally using Bortfeld’s
method of optimisation for the weighting functions for idealised asymptotic Bragg
curves (Bortfeld, 1996), I found this method was not sufficient for Bragg curves
with more realistic considerations (no asymptote). The resulting SOBPs always
had negative gradient using this formulation. However the formulation which was
contained in the Bortfeld 1996 paper for the weighting factors (W) depending on
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range (R) and regular spacing (∆), W∆(R) did give upper and lower bounds by
using a conservative factor of 10 on the values to set the upper bound.
The mutations I define as consisting of positive or negative increments of each
weighting function value up to the size of the desired maximum mutation (a +ve or
-ve time based random number change). The concept of converging and diverging
mutations is defined as: if new best genetic solutions are not being found fre-
quently enough then the program automatically reduces the size of the maximum
mutations and similarly if the new best genetic solutions are being found too fre-
quently the program automatically increases the maximum size of the mutations.
In benchmark tests of fixed value vs converging/diverging the converging/diverging
method has consistently produced lower flatness values (using a standard χ2 eval-
uation mechanism). Another advantage is that the user now doesn’t need to
estimate the maximum size of the mutations for a given maximum iteration limit
(smaller mutations require more iterations to converge on the optimal solution).
For the first part the method used in the program was to generate the set of
weighting functions between W∆(R) and 10W∆(R) with the additional considera-
tion that the more distal values must be greater, if a configuration is found which
produces a resulting χ2 value which is less, then it keeps this new configuration
as the best for the normalised weighting factors. In the second part it starts with
the best configuration generated by the Bortfeld W∆(R) function limits and per-
forms ‘mutations’ on each weighting function value in the array. In this part of the
procedure, there is no condition implemented that the more distal values must be
greater, as the optimisation mechanism naturally achieves this and it may skew
the results to implement this condition. After each set of mutations, the program
computes the χ2 value again between the limits. Performing this Monte Carlo
2.3. SPREAD OUT BRAGG PEAKS (SOBPS) 41
optimization over many iterations, the ‘best genetic solution’ can be found, some
of these results are shown in figure 2.3.
Figure 2.3: Post SOBP optimisation results for the flat regions as defined. Very
flat results found across all ouputs at ∼0.1% flatness (given sufficient iterations).
2.3.3 Conclusions
In this technical investigation, I have examined an algorithmic method using evo-
lutionary Monte Carlo optimization for Bortfeld Bragg peaks for SOBPs. I have
found that my results produced flatnesses at least 10 times better than any other
current published methods as referred to in section 2.3.1. In principle there is no
ceiling for how accurate this method can be, given enough iterations of the opti-
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mization and small enough mutation sizes. The computational time was found to
be not insignificant, using sub-optimal efficiency code, of the order of 10 minutes
per optimization using typical parameters. It is understood that there are other
practical factors which limit the practical use of such an algorithm to find better
flatnesses of SOBPs for use clinically, however it was not investigated as a part of
the PhD project.
2.4 Theory of X-ray Depth Dose
In this project reference will also be made to X-ray irradiation. Therefore it is
useful to have a model for dose deposition for X-rays and one is presented here. The
theoretical model used in this section is adapted from the paper by Wierzbickit et
al., 1993. In this paper, the model the authors used to fit a depth dose curve to the
X-ray dose can be described in its simplest form as the summing of two exponential
functions, and this was compared to, and verified against, measurements from a
phantom. In the paper the authors state that many algorithms currently used for
dose calculations require fixed maximum dose values (Pike et al 1987, Luxton et
a1 1991, Podgorsak 1992), and that in their proposed analytical representation of
depth doses (for X-rays), this limitation would be overcome.
The method used is for photon beams which are generated using voltages of
6MV, 10MV and 18MV. The authors state that the depth of the maximum dose is
proportional to the photon energy. The theoretical formulation is given as follows,
the percentage depth dose (PDD) is given by:
PDD = A1e
−β1d − A2e−β2d (2.22)
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Figure 2.4: The lateral profile for an X-ray beam with parameters as listed on this
figure (the vertical axis represents the percentage of maximum dose). This will be
useful later in this project where I will model the lateral profile of X-rays as an
approximate step function for use in the simulations (Alaei et al., 2012).
In Eq. (2.22) it is seen that this formulation for the PDD of X-ray irradiation
depends on the sum of two exponential terms with constants which are to be
determined (A1,2 and β1,2) and the depth d in consideration. The field size is given
as a square field e.g. 6×6cm2, 10×10cm2, 20×20cm2. In order to determine the
values of the parameters used in Eq. (2.22), the authors provide graphs contained
in the paper where the values for the constants can be read off.
In order to ready this formulation for use in this project I decided on the
associated parameters for a 10cm × 10cm field size for the photon beam, and
6MV generated photon beam. Then reading from the figure which is presented in
the paper to determine the constants to find: A1 = 110, β1 = 0.0064, A2 = 96,
β2 = 0.34. Therefore with these values the depth dose equation becomes:
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PDD = 110e−0.0064d − 96e−0.34d (2.23)
From straightforward dimensional considerations of the above equation, the units
of depth are in mm. Therefore there is now a readily available formula for use in
the simulations in this project for X-ray irradiations.
Figure 2.5: An outcome of plotting X-ray depth dose using the theoretical model
presented by Wierzbickit et al., 1993 with parameters as listed on this figure.
Chapter 3
Mathematical Models Which
Describe Biological Effect on
Normal and Cancerous Tissue in
the Lung
In this chapter the aim is to cover the relevant literature for the investigations of
this project. Therefore sub-dividing by section, critically analysing and discussing
topics, describes how this project fits in with the relevant background work and
what this project adds which is new and novel. Firstly a review of lung fibrosis or
NTCP calculation based methods will be discussed. Then a discussion of updates
since the QUANTEC study was first published in 2010 will be presented. Finally,
a review of proton relative biological effect in the literature will be discussed.
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3.1 Review of Lung Fibrosis or NTCP Calcula-
tion Based Papers
Examining the sources in the literature which confirm that EUD is a widely used
method for proton based NTCP calculation modelling; Rana et al 2014 employed
the EUD variable as the one which characterises the dose distribution for the pro-
ton prostate plans they were investigating and for calculating NTCP. The authors
state that their EUD evaluation was performed using the dose-volume histograms
(DVHs) of the treatment plans, which were exported from their treatment planning
software. Specifically, they utilized the DVHs of the treatment plans (VMAT1 and
protons) to calculate the EUD, which is based on Niemierko’s phenomenological
model (Niemierko and Gay, 2007) which will be discussed later in this section.
This phenomenological model is the one employed in this project.
An important question for this project is how to consider the lung for modelling
purposes. Given that in this project I am constructing a model of human lungs to
simulate irradiations with, it is therefore important to address the question of the
size of the lungs which need to be constructed as one of the modelling parameters.
Therefore a particularly relevant study is the one conducted by Kramer et al.,
2012, where the authors address the question of how to consider the lung for mod-
elling purposes. They state that the lung is usually considered as a single, paired
organ (total lung tissue) rather than as separate ipsi- and contra-lateral lungs.
In this paper, the authors state that the results are inconsistent both for the best
predictive metrics and significant co-morbid factors and since metrics2 will be used
1Volumetric modulated arc therapy: a type of intensity modulated radiotherapy (IMRT)
2A metric is a parameter which can be used for dose-volume characterisation e.g. Vx
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in this project, this is an important statement. The authors present a discussion
of the Lyman-Kutcher Burman (LKB) DVH-reduction scheme and Mean Lung
Dose (MLD), where they make reference to the data set for Vx against incidence
of lung fibrosis in %, which was the figure given in the original QUANTEC study.
Kramer et al state that various Vx values are associated with radiation pneumoni-
tis risk with reference to the QUANTEC study. These authors then assert that
the observation that a variety of dose levels are predictive suggests that there is
no sharp threshold for dose below which there is no risk. Further, they state that
within individual data sets there are usually strong correlations between the dosi-
metric parameters e.g. V5 and V20. The authors also state conclusively that the
correlations between dosimetric parameters are technique dependent and readers
should carefully assess the similarity of their treatment technique before using any
of these limits as clinical constraints. Without explaining their CT-based method
used to determine the sizes of the lungs in detail, a compilation of the data points
gathered for linear lung dimensions was displayed and the mean values were taken
for dimensional width of lung. The principle importance of this paper in the con-
text of my study was for the construction of the appropriate dimensions of the
lung model. In my study values were taken using male lungs from the Kramer
et al., 2012 paper, with the appropriate benchmark being performed later, as ex-
plained in Appendix D and Chapter 5 of this report. Kramer et al, 2012, state in
their paper that a predictive formula does not exist for the linear dimensions due
to the large number of independent variables. However, the data presented are
more modern than the brief table that appeared in International Commission on
Radiological Protection (ICRP) 23, and the average values could be used as future
guidelines, and are utilised for my study.
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Figure 3.1: A geometrical approach to modelling NTCP effects within the lung
(Rutkowska et al., 2012). The purple region represents a tumour and the blue
region represents the lung volume.
Rutkowska et al., 2012 have shown that it is possible to make sense of the
way the lung responds to radiation by modelling radiation pneumonitis mechanis-
tically, from cell death to tissue damage to loss of organ function and is therefore
an important statement for this work. The authors state that when considering
the structure of the lung, two factors in particular should be important when esti-
mating the risk of toxicity: the dose threshold for significant local tissue damage
and the volume of damaged lung. In particular this paper was an inspiration for
the construction of the geometry of the lungs for simulation as shown in figure 3.1.
It is important also in this project to have an understanding of the incidences
of radiation pneumonitis and the appropriate grading structure as a more general
overview of the disease. Marks et al., 2010, state RT plays an important role in the
treatment of several tumours in and around the thorax (and hence the lung tissue).
Specifically, that clinically-significant symptomatic radiation pneumonitis occurs
in ∼5-50%, ∼5-10% and ∼1-5% of patients irradiated for cancers of the lung,
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mediastinal lymphatics and breast respectively, and is one of the most common
toxicities in these patients. The authors state that the risk of such incidence
of radiation pneumonitis may thus hamper tumour control by limiting the dose
delivered.
Seppenwoolde et al., 2003 also contains an assignment of the grading structure.
The authors divide the severity of radiation pneumonitis occurring in the first 6
months after treatment according to the Southwest Oncology Group toxicity cri-
teria: Grade 1 (mild) radiation pneumonitis applies when radiographic changes
(on chest radiographs or CT scans) are observed but the symptoms do not re-
quire steroids. Grade 2 (moderate) is scored when steroids are required. Grade
3 (severe) oxygen is needed. Grade 4 (life threatening) assisted ventilation is re-
quired. The authors state that the probability of developing radiation pneumonitis
after treatment with high-dose radiotherapy is important for patients with inoper-
able non small cell lung cancer (NSCLC). The authors state that severe radiation
pneumonitis during the first 6 months after irradiation may be life threatening.
Furthermore, in this section, the authors state that the probability of develop-
ing radiation pneumonitis (lung fibrosis) is important for patients with NSCLC
who undergo radiation treatment (radiotherapy). Finally a general comment that
the paper states that knowledge about the relationship between the three dimen-
sional dose distribution and the incidence of radiation pneumonitis is essential for
designing a treatment plan that maximises the tumour dose and minimises the
NTCP.
Upon examining the available literature it is clear that due to the complexity
of the subject matter it can be prudent to define thresholds on the metrics in ques-
tion which are available for NTCP modelling. Marks et al., 2010 conclude that
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it is challenging because there are no clear thresholds for candidate metrics, the
response function is often gradual and the acceptable risk varies with the clinical
scenario. The authors then state that despite these caveats, it is prudent to limit
V20 to ≤ 30 − 35% for conventional fractionation if the risk of inducing radia-
tion pneumonitis is to be limited to ≤ 20%, in definitively treated patients with
NSCLC. The authors further state that in patients treated post-pneumonectomy
for mesothelioma, it is prudent to limit the V5< 60%, the V20< 4− 10% and the
MLD< 8Gy.
It is stated in the Seppenwoolde 2003 paper previously mentioned that the
V20 is the most significant predictor of radiation pneumonitis. Similar findings
were reported by Marks et al (Marks et al., 1997) for the lung volume receiving
at least 30Gy (V30). Furthermore, although all the studied parameters showed
a good correlation with the incidence of radiation pneumonitis, no consensus has
been reached about what is the best model to predict radiation pneumonitis. The
conclusion from the Graham et al. paper, 1999 is quoted that V20 was revealed
by multivariate analysis to be the most significant predictor of radiation pneu-
monitis. A conclusion from other papers about a dose-volume behaviour is stated:
Armstrong et al. found a higher incidence of grade 3 pneumonitis for patients
with > 30% of their lungs irradiated with > 25Gy compared with patients with a
smaller V25.
In the original QUANTEC paper by Bentzen et al., 2010, the review sum-
marised the then most up-to-date three-dimensional dose/volume/outcome data
to update and refine the normal tissue dose/volume tolerance guidelines provided
by the Emami et al. paper, 1991. A “clinicians view” on using the QUAN-
TEC information in a responsible manner is presented along with a descrip-
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tion of the most commonly used NTCP models. A summary of organ-specific
dose/volume/outcome data, based on the QUANTEC reviews is included. The
Marks et al., 2010 paper is also an important study which is referred to through-
out the thesis and provides reference to the QUANTEC study. The authors state
that in this paper, the three dimensional dose/volume/outcome data for lung are
reviewed in detail.
In the Bentzen et al., 2010 paper the authors reviewed advances in dose-
volume/outcome (or NTCP) modelling since the “seminal” Emami paper from
1991. The authors state there has been some progress with an increasing number
of studies on large patient samples with three-dimensional dosimetry, nevertheless,
that NTCP models are not ideal. Synthesis (meta-analysis) of data from multi-
ple studies is often impossible because of suboptimal primary analysis, insufficient
reporting and variations in the models and predictors analysed. It is stated in
the paper that clinical limitations to the current knowledge base include the need
for more data on the effect of patient-related cofactors, interactions between dose
distribution and cytotoxic or molecular targeted agents, and the effect of dose
fractions and overall treatment time in relation to non-uniform dose distributions.
This paper states in the introduction that QUANTEC is going to be applied across
the various methods of radiotherapy including proton therapy to summarise the
available 3D dose volume/outcome data. The paper states further that the NTCP
effects are typically under-reported and under-recorded which is of particular im-
portance when considering analysing NTCP effects. The Emami et al., 1991 paper
published the tolerance doses for irradiation of one third, two thirds, or the whole
of various organs. This paper mentions having DVH based NTCP models, saying
that they are the most frequently used. The authors state that extensive stud-
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ies by van der Kogel in the late 1980s showing that the probabilistic model did
not correctly predict the probability of spinal cord injury after irradiation of two
geometrically separated 4-mm segments of rat cervical spinal cord undoubtedly
discouraged further exploration of their model in the analysis of clinical datasets
(Stewart et al, 2002). Van der Kogel’s studies were subsequently expanded into
a systematic study of dose-volume effects in the rat spinal cord, ending with the
sobering conclusion that none of the 14 mathematical models, tried by the authors,
could fit all the data (van Luijk et al., 2005).
The paper by Gay and Niemierko 2007 was important for use in my work as
an EUD based calculator. The purpose of this was to provide a research tool that
may be used to calculate the NTCP or TCP of a particular treatment plan and
to illustrate the implementation of the EUD-based NTCP and TCP models as a
research tool. The methods the authors used were to computationally implement
Niemierko’s EUD-based NTCP and TCP mathematical models. From this paper
adapted from the Emami et al. normal tissue tolerance data when radiation is
delivered in 1.8-2Gy fractions, it is stated the following parameter values for lung
tissue: a = 1, γ50 = 2 and TD50 = 24.5Gy. It is stated in the Niemierko 2007 paper
that the TD50 is the tolerance dose for a 50% complication rate at a specific time
interval (e.g. 5 years in the Emami et al., 1991 normal tissue tolerance data) when
the whole organ of interest is homogeneously irradiated, and the γ50 is a unitless
model parameter that is specific to the normal structure of tumour of interest and
describes the slope of the dose-response curve. It is further stated in this paper
that parameters a and γ50 should be obtained by fitting clinical dose-response data
to the EUD based NTCP or TCP model. These data values will be utilised further
in this thesis for use in their EUD model presented.
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In the Niemerko et al., 2007 paper the authors state that over the past decades,
there have been many attempts to develop NTCP and TCP mathematical models
(Warkentin et al., 2004), (Jackson et al., 1993) and (Burman et al., 1991), and that
the complexity and computer skills required by some of these models often alienates
clinicians from this area of research. Various NTCP mathematical models based on
retrospective data that correlate with clinical outcome exist for specific organs at
risk such as the rectum (Rancati et al., 2004) and lung (Seppenwoolde et al, 2003).
It is stated that many of these models have been used primarily as research tools.
The authors state that their goal was to provide a research tool that may be used
to calculate the NTCP or TCP of a particular treatment plan, and ignite further
interest in this research area. In their introduction to the EUD-based NTCP
and TCP mathematical models, they state that the EUD-based mathematical
model (Niemierko, 1999) is simple because it is based mainly on two equations,
and versatile because the same model may be used for both TCP and NTCP
calculations. The model has an excellent ability in fitting, for example, the Emami
et al. normal tissue tolerance values (Emami et al., 1991) (as shown in figure
3.2 - this is for brain values but similar principles apply for lung). The original
definition of the EUD was derived on the basis of a mechanistic formulation using
a linear-quadratic cell survival model (Wu et al., 2002). Subsequently, Niemierko
has suggested a phenomenological model of the form:
EUD =
(
ΣNi=1viD
a
i
)1/a
(3.1)
Eq.(3.1) can be used for both normal tissues and tumours. a is a unitless model
parameter specific to the normal structure or tumour of interest. vi represents the
3.1. REVIEW OF LUNG FIBROSIS OR NTCP CALCULATION BASED
PAPERS 54
normalised ith partial volume receiving dose Di in Gy; with Σ
N
i vi = 1. The authors
state that for normal tissues, the EUD represents the uniform dose which leads to
the same probability of injury as the examined inhomogeneous dose distribution.
NTCP =
1
1 +
(
TD50
EUD
)4γ50 (3.2)
Marks et al., 2010 state that using a logistic fit to data they presented, their
estimates yield a predicted TD50 = 30.8[28.7, 33.9]Gy and γ50 = 0.97[0.83, 1.12].
When I saw these values I noticed there was a difference between these and the ones
presented in the 1991 Emami paper so hence I chose to divide the parameter sets
into “Marks” and “Emami” parameters and perform investigations based on the
two respective parameter sets. Furthermore the authors state that approximately
80% of radiation pneumonitis is clinically manifest within 10 months of RT, giving
a time frame for the development of lung fibrosis.
Alternatives to the EUD model include the MLD and the LKB model. Here I
would like to briefly discuss the possible limitations on the use of an MLD based
model from the literature. Tucker et al., 2012 state that the parameter most often
used to quantify radiation exposure to lung is the MLD. This study by Tucker
et al., 2012 was investigating the relationship between the different physical dose
distributions and probability of lung fibrosis for a given MLD for lung cancer,
and further to offer a replacement for MLD that might better predict the risk of
lung pneumonitis. It is further stated that the QUANTEC survey of dose-volume
effects in lung illustrates a fairly consistent relationship between MLD and risk
of symptomatic radiation pneumonitis in 10 different studies (Marks et al., 2010).
The LKB model is another popular alternative NTCP model but is relatively
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Figure 3.2: Complication probability vs. dose for the brain (Gay and Niemierko,
2007). The EUD-based NTCP mathematical model was used to create three dif-
ferent brain volume curves to fit the Emami et al. data using the following model
parameters: TD50 = 60 Gy, a = 5, and γ50 = 3. In this model the organ volume
is typically split up into 1/3, 2/3 or the whole organ as shown in the figure.
complicated mathematically.
It is further stated in the Tucker et al., 2012 paper that nonetheless, there are
reasons to expect that MLD by itself is not adequate as a predictive dosimetric
parameter. Patients who undergo an array of different treatment plans may share
the same MLD, and it seems reasonable to expect that there could be differences
in complication risk between patients receiving high doses to a small lung volume
(“a lot to a little”) and those receiving low doses to a large volume (“a little
to a lot”) (Willner et al, 2003). Accordingly, most institutions use additional
dosimetric constraints together with MLD. The authors state their chosen dose-
volume constraints used for lung since approximately 2006 are MLD of ≤20 Gy, a
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volume receiving more than 5 Gy (V5) of ≤65%, and a V20 of ≤37%.
3.2 Update Since QUANTEC
When matching calculation methods to data based results it was important for
the project to know that the results available are up to date. Therefore there was
the task of finding any progress in data sets since the 2010 QUANTEC study had
been published.
Jackson et al., 2010 outline requirements for future QUANTEC efforts. It is
stated that severe normal tissue complications are, by good medical practice, rela-
tively uncommon. Investigations of their causes will inevitably be plagued by the
small number of events in individual series. The authors state that it is therefore
important to be able to combine complication data from different institutions and
protocols. This can be achieved in two ways: by the direct combination of raw
data (i.e., pooling of dose distribution and outcome information); or by combina-
tion of published results (literature-based meta-analysis). The authors state that
the initial efforts of QUANTEC have concentrated on the second approach. In
the process of gathering and analysing the published data for the papers on this
issue, the limitations of existing journal articles as sources for meta-analysis have
become apparent. They fall into two major categories: first, the low and uneven
standards of reporting results; and second, the difficulty of defining common and
meaningful clinical endpoints (Jackson et al., 2010).
Appelt et al., 2014 state that understanding the dose-response of the lung in
order to minimize the risk of RP is critical for optimization of lung cancer radiother-
apy. The authors state that they proposed a method to combine the dose-response
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relationship for radiation pneumonitis in the QUANTEC paper with known clini-
cal risk factors, in order to enable individual risk prediction. The authors of this
paper give that the impact of clinical risk factors on the probability of radiation
pneumonitis after curative radiotherapy for lung cancer is a much-studied issue.
However, a consistent quantification of the effect on the dose-response has proven
challenging, partly because of the demands on data quantity and completeness re-
quired for a multivariate analysis taking all relevant factors into account. Further
it is stated in Appelt et al., 2014 that a major step forward for the understanding
of the dose-dependence of radiation-induced lung toxicity was represented by the
organ specific paper from the QUANTEC initiative, which performed a collective
analysis on a number of published studies. The authors related MLD to the risk
of radiation pneumonitis for NSCLC patients, and provided a quantitative esti-
mate of the dose-response relationship. The authors state that this represents an
impressive and important undertaking, which will aid both clinical dose planning
and design of future RT studies. Furthermore, the published dose-response rela-
tionship is an estimate of the risk in an ‘average’ NSCLC patient. Also it is stated
that prediction of the risk of radiation pneumonitis for individual patients is still
fraught with uncertainties, and this may be part of the reason for the limited
predictive power of even the best published models.
Returning to the issue of the importance of accurate dosimetric parameters
in order to predict radiation pneumonitis risk, in the previously mentioned Jack-
son et al., 2010 paper, it is stated that individual studies may give dose volume
constraints or perform model fits but results from different studies cannot be com-
bined unless the same dose volume constraints or model parameters are considered.
The authors state that the fundamental difficulty lies in the large number of dose
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volume variables to be tested. Further, they state that to address this problem
through the literature requires adoption and creation of tools for comprehensive re-
porting such as dose-volume and EUD Atlases of Complication Incidence (Jackson
et al, 2006).
The paper from Tucker et al., 2012 also addresses this issue; the authors stated
that the results of their study demonstrate differences in the risk of severe radiation
pneumonitis among patients having the same mean dose but treated with different
beam configurations and therefore having different dose distributions to lung. The
conclusion for this paper is stated that their findings, if confirmed, suggest that
the MLD does not take into account adverse effects of high doses and should
be replaced by a better dosimetric parameter of radiation pneumonitis risk (e.g.
Deff
3).
On the issue mentioned in the literature of the limitations on the predictive
power of the models, in the previously referred to paper by Appelt et al., 2014,
it is stated that a great many studies have proposed predictive models for the
risk of developing radiation pneumonitis after curative radiation therapy (Marks
et al, 2010). Further, that although progress has been made (Palma et al, 2012),
a considerable challenge remains with the generalisability of such models. The
authors state here that even when sophisticated statistical techniques are employed
in order to avoid over-fitting, model results may not be generalisable to different
patient cohorts (Bradley et al, 2007).
To summarise, the previously mentioned paper by Jackson et al., 2010 pro-
vides a concise summary that the development of side effects after cancer therapy
is inherently multifactorial and much of the variability in response is currently
3This is an alternative notation for EUD
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unexplained by dosimetric factors alone.
3.3 Review of Relative Biological Effect Papers
In this project it is also important to consider the effects of proton RBE. The uncer-
tainties in RBE have been described as contributing the main source of uncertainty
to proton treatment delivery overall (Loeﬄer et al., 2013) and this important point
will be returned to in the next chapter when considering the effects of these pos-
sible uncertain input parameters to the analytical RBE model being used in this
project.
Regarding the current uncertainties on RBE, the Durante 2014 paper states
that particle radiobiology is entering a new phase where beyond RBE, the tissue
response is considered. It is asserted that uncertainty on RBE is very high and in-
deed the main source of uncertainty in estimates of cancer risk and dose estimation
in charge particle therapy (Loeﬄer et al., 2013). It is generally acknowledged that
corrections should be used (deviating from the universally used 1.1 constant value
of RBE) at least in the distal part of the SOBP where radiobiology shows that
slow protons have an increased biological effectiveness (Carabe et al., 2013). The
increase of RBE with depth causes a shift of the fall-off of the proton beam i.e. a
change of the beam range (biologically effective range), (Carabe et al., 2012, Grun
et al., 2013). Further, uncertainty on the RBE is often quoted as a major hinder-
ance to a widespread use of heavy ions in radiotherapy and is a source of concern
for the potential late effects. Durante states that predicting risks to individuals
is difficult as there are very few quantitative measures of individual sensitivity.
This paper also includes the graph as shown in figure 3.3 which appears to show
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an relatively high peak in RBE weighted dose at the distal end more than ×2.0
relative to the physical dose.
Figure 3.3: Very sharp peak for RBE at the distal end of the SOBP (Durante,
2014).
Similarly, Chaudhary et al., 2014, write that proton therapy is currently the
fastest growing cancer treatment strategy, attracting considerable interest from
industry, as well as the academic and health care sectors (Suit et al., 1990). They
state that in addition to the favorable dose distributions made possible by the
Bragg peak, successful implementation of any kind of ions used for radiation ther-
apy critically depends on their RBE (Levin et al., 2005). Furthermore it is stated
that any uncertainty in RBE translates directly into uncertainty of the biologically
effective dose (physical × RBE) delivered to the patient, which strongly under-
mines the ±3.5% requirement for dose accuracy in clinical settings (Brahme et al.,
2000, Paganetti et al., 2002).
Another good reason to consider the effects of a possibly larger RBE is due to
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the increase in beam range which is provided. In clinical proton therapy, clinicians
take this range increase into account even though no variable RBE may be included
in the Treatment Planning Systems (TPS), when planning treatments particularly
when the dose distribution is abutting a critical organ at risk (Paganetti 2003).
In the Chaudhary et al., 2014 paper previously referred to the authors state that
there may be as much as a 3 mm increase in estimated range when a variable RBE
weighting is used during treatment planning (Carabe et al., 2012). Importantly,
in the same paper the authors also state that in general, as LET increases, the
RBE increases, eventually reaching a maximum and then decreasing (Goodhead,
1990). The authors give a multitude of literature sources to draw the conclusion
that based on these considerations a small increase in the proton RBE across the
SOBP and the extension of the penetration of the beam by a few mm is expected
because of an increasing LET (Paganetti et al., 1997; Paganetti 1998, Paganetti
and Goitein, 2000; Wilkens and Oelfke, 2004). Later in the paper it is stated that
this fact therefore needs to be considered in treatment planning. Similarly, it is
stated in the paper that the increase in RBE as a function of depth in an SOBP
also impacts the position of the distal dose fall-off. An increasing RBE with depth
can lead to a shift in the fall-off (physical dose versus biological dose) of up to
4 mm, depending on dose and (α/β)x (Robertson et al 1975, Carabe et al 2012,
Matsumoto et al 2014)4.
On the same subject, Paganetti 2003 states that elevated RBE values and a
clinical impact could be expected at the distal end of a treatment field. Finally,
this notwithstanding, to increase treatment accuracy the implementation of RBE
variations in treatment planning is certainly desirable. It is further stated that
4Linear Quadratic (LQ) model is introduced in chapter 4.
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model calculations can only be as accurate as the biological cellular experiments
from which the model parameters were extracted. This final statement is a topic
which will be returned to in chapter 4 of this thesis.
Here I would like to discuss the experimental data associated with computing
the proton RBE and the associated uncertainties from the perspective of the ex-
isting literature. Paganetti and Bortfeld 2005 state that protons are slightly more
biologically effective than photons. The authors state that the fundamental reason
for applying an RBE value is to ensure that the radiation oncologists can benefit
from the large amount of clinical data obtained from photon beams. Then in the
paper a formal equation definition of RBE is presented. The authors state that
a value of 1.1 is applied in general to proton treatments, independent of dose per
fraction, position in the SOBP, initial beam energy or the particular tissue type
being irradiated. The authors further state that the generic RBE (of 1.1) is only a
rough approximation considering experimentally determined RBE values for both
in vitro and in vivo work (Paganetti 2002, Paganetti 2003).
On the similar subject of the experimental data which composes the acccuracy
of the overall proton RBE, Paganetti writes in 2014 that for the purpose of defining
clinical RBE values only experimental data on clonogenic cell survival are available
in large quantities. Thus, RBE values currently can be defined only based on these
data (albeit with still large uncertainties).
In 2003, a quantitative measure of the estimated RBE is provided in the paper
by Paganetti and compares results found for in vivo and in vitro methods; for the
in vitro data from clinical beams, the range of estimated RBEs in the center of
the SOBP is from 0.86 to 2.1 with a mean of 1.22 and a standard error of 0.02.
I would make a comment here that the value of 2.1 seems quite large for these
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measurements for RBE particularly when considering the fixed clinical value of
RBE of 1.1 in use. The in vivo RBEs (mid-SOBP) range from 0.73 to 1.55 with a
mean of 1.10 and a lower standard error of 0.01. Thus, there appears to be a lower
RBE with a lesser spread in vivo than obtained from in vitro systems. Further
it is presented that the low energy proton data show, not surprisingly, a higher
average RBE (mean RBE is 1.71 ± 0.69 at doses >1 Gy).
Finally, it is stated in the aforementioned 2014 Paganetti review that delivery
uncertainties in proton therapy are being reduced based on research in many areas,
potentially leading to a reduction in margins, which in turn might expose RBE
variations (Paganetti 2012, Carabe et al 2012, Schuemann et al 2014). Paganetti
states that given the large amount of data it is surprising that the RBE for clinically
relevant LETd values, α/βx values and doses is still associated with considerable
uncertainties. This paper states that it is recommended to consider (α/β)x as well
as estimating LETd in regions of interest, or even on a voxel-by-voxel basis. The
question of the impact of these uncertainties is addressed in this thesis. A voxel
by voxel basis is adopted in this thesis.
It appears upon examination that there are areas of the literature which con-
tradict others to conclude that a fixed value of RBE of 1.1 is limitative and can
be improved upon. The first instance is shown here in Chaudhary et al., 2014.
In this paper the authors importantly conclude that the adoption of a constant
RBE of 1.1 appears to be limitative and inadequate; a statement which is in direct
contradiction with some of the other literature on the same subject. The authors
also further state that using the data obtained in their study leads to an under-
estimation of the biologically effective dose delivered to the SOBP of up to 18.3%
and 17.9% respectively by the treatment using RBE= 1.1. The conclusion from
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this paper is that the answer would be to use a variable RBE as this would lead
to an optimization of proton therapy and closer outcome predictions.
This similar subject is also discussed in the aforementioned Chaudhary 2014
paper, in which they found that RBE increase is apparent in all cases at the distal
end, reaching values well above the clinically used RBE value of 1.1. It is worth
noting here that this paper just refers to 60MeV protons which are much lower than
typical IMPT energies and these have seen some use clinically for ocular tumours.
It is also interesting here to find that the formulation which is used in this paper for
the RBE is the same as the Wilkens and Oelfke paper on RBE. In this paper they
assumed a constant value of β and also that αp = αx + λLET which is also what
is given in the Wilkens and Oelfke paper which is later discussed in this thesis.
The value of λ which was used in this paper is λ = 0.0451µmkeV−1Gy−1 and
0.0127µmkeV−1Gy−1 for their studied cell lines. The context of these equations
will be discussed in the next chapter.
One of the important conclusions of the 2014 Paganetti review paper is written
that data on RBE for endpoints other than clonogenic cell survival are too diverse
to allow general statements other than that the RBE is, on average, in line with a
value of ∼1.1. At the beginning of this review paper Paganetti states that proton
therapy treatments are based on a proton RBE relative to high energy photons of
1.1. Furthermore, the use of this generic, spatially invariant RBE within tumors
and normal tissues disregards the evidence that proton RBE varies with LET,
physiological and biological factors, and clinical endpoint.
Simply comparing the final two reviewed papers in this section from Durante,
2014 and Chaudhary 2014 to the reviews from Paganetti, it is clear that there is a
conflict between these papers in conclusion whether to accept a fixed clinical RBE
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value of 1.1 as absolutely adequate.
Addressing the question of how large the increase in effective dose is at the distal
end, Paganetti 2003 states that the published RBEs do suggest a modest increase
with depth in the SOBP. Further, there is a relatively clear rise in effective dose in
the region close to the distal end of the SOBP, and a modest few mm extension in
depth of the effective dose distribution. Reported RBE values for the 65 - 100 MeV
protons tend to increase gradually throughout the SOBP (Blomquist et al, 1993,
Courdi et al, 1994). This trend was less pronounced for high energy beams having
wider SOBPs (Coutrakon et al, 1997, Slabbert et al, 1994, Robertson, 1975). It
is stated that a fit of all available RBE values determined over the SOBP showed
an increase in RBE of about 5% at 4 mm and about 10% at 2 mm from the distal
edge, relative to the mid-SOBP RBE. The effects of an increasing RBE with depth
could be compensated for in the physical dose distribution since for some endpoints
at least relative RBE values are known well enough.
It is further stated in the 2014 Paganetti review that despite the large amount
of data, considerable uncertainties in proton RBE values remain. Paganetti writes
that as an average RBE for cell survival in the center of a typical spread-out Bragg
peak, the data support a value of ∼1.15 at 2 Gy per fraction. The proton RBE
increases with increasing LETd and thus with depth in an SOBP from ∼1.1 in the
entrance region, to ∼1.15 in the center, ∼1.35 at the distal edge and ∼1.7 in the
distal fall-off.
It is stated in this paper that current clinical practice adopts a constant RBE
value of 1.1 across the entire SOBP irrespective of its size, beam modulation, depth,
cellular radiosensitivity, and the delivered dose (Jones et al., 2011, Blomquist et
al., 1993). Furthermore, the use of a single RBE value for protons is complicated
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because the RBE also depends on the dose per fraction, number of fractions, tissue
types, level of oxygenation, and the biological endpoint (Mohan et al., 2013). In
vitro studies reported proton RBE values increasing along the SOBP reaching
1.4-1.6 (Belli, 2000, Robertson, 1975, Courdi, 1994, Wouters, 1996).
Finally, there is a consensus in the literature that an adaptation of the dose
response model is needed when considering proton RBE. It is stated in the pre-
viously referred to 2014 Chaudhary paper that current clinical practice adopts a
constant RBE value of 1.1 across the entire SOBP irrespective of its size, beam
modulation, depth, cellular radiosensitivity, and the delivered dose (Jones et al.,
2011, Blomquist et al., 1993).
A general comment on the importance of adapting the dose response model is
made by Paganetti in the aforementioned 2003 paper, where it is stated that due
to the increasing number of patients treated with protons more and more patients
will be considered as potential proton therapy candidates. In order to quantify
accurately the relative merits of treatment modalities and treatment techniques, it
is important to adopt biologically sound cellular dose-response models for tumors
and normal tissues and implement them into treatment planning. The warning is
given that despite these studies, one should be cautious of interpreting theoretical
RBE values. Dependencies of RBE values on specific physical or biological pa-
rameters may not be true model predictions but may be a result of the underlying
theory on which the phenomenological model is based. By design, models based
on the track structure theory exclude proton RBE values lower than 1.0 and also
demand an increasing RBE with decreasing dose.
On the subject of adapting the dose response model, it is stated in the afore-
mentioned 2014 review paper by Paganetti that proton dose distributions in criti-
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cal structures are typically more heterogeneous compared to photon therapy. Yet
most dose constraints are defined based on mean dose. The RBE values extracted
from cell experiments are valid for homogeneous doses and would thus need to be
applied on a voxel-by-voxel basis if used clinically. It is stated that the definition
of RBE for NTCP requires a voxel-by-voxel analysis with potentially defining a
concept like the equivalent uniform biological dose similar to the equivalent uni-
form dose concept (Niemierko 1999). This holds not only for applying variable
RBE values but also when analyzing treatment outcomes with respect to potential
RBE variations (Sethi et al 2014, Giantsoudi et al 2014).
Durante also refers to this point in the 2014 paper “New challenges in high
energy particle radiobiology”. It is written in the paper that RBE is in fact
a function of several factors, often non-independent: biological end point, tissue
type, proliferation status, dose, dose rate, oxygen concentration, culture conditions
(in vitro) or metabolism (in vivo) and so forth. Moreover, that modelling will
always be necessary for including RBE in the treatment planning, and here, there
is room for improvements switching from phenomenological to mechanistic models
(Friedrich et al., 2012). It is also written that it is worth noting that although
the uncertainty in RBE is certainly a problem in heavy ion therapy, it should not
prevent the use of this treatment modality, owing to the lack of significant side
effects observed so far in Japan and Europe.
Chapter 4
Relative Biological Effect (RBE)
Modelling: Effects of
Uncertainties
4.1 Introduction and Theory of Model
Model calculations of RBE can only be as accurate as the biological experiments
from which the model parameters are extracted (Paganetti, 2014). This subject
will be covered in this chapter: where the uncertainties on the input parameters
to the 2004 Wilkens and Oelfke RBE model will be investigated. The effects of
these uncertainties will be simulated in a one dimensional model of the lung to find
out the resulting changes in RBE and how this relates to NTCP within the EUD
model. This may be of particular significance given the size of the uncertainties
on the input parameters is quite large.
There are two different variations in assumptions which will be simulated, firstly
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the difference in the TD50 and the a parameters which are being used - different
input values for the EUD model from the Emami et al., 1991 and Marks et al.,
2010 data sets respectively. However the main source of variations will be within
the RBE model. Furthermore, the uncertainties in RBE have been described as
contributing the main source of uncertainty to proton treatment delivery overall
(Loeﬄer et al., 2013). Therefore it is important to consider the possible effects of
these uncertainties.
In order to have a working RBE calculation it was required to have a model
for LET and new concepts were investigated within this PhD which are contained
in Appendix F in addition to the reason the new concepts are necessary. Using
the 2004 Wilkens-Oelfke phenomenological model for RBE, it is found RBE is
a function of energy. The RBE also depends on biological endpoint (e.g. cell
survival) and tissue specific parameters. In their 2004 paper Wilkens and Oelfke
state that their model was able to reproduce the basic dependences of RBE on dose
and LET, and the RBE values agreed well with experimental results. In the paper
the model was also applied to spread-out Bragg peaks, where the main effects of
a variable RBE are an increase of the RBE along the SOBP plateau, and a shift
in depth of the distal falloff. In the linear quadratic model, the surviving fraction
SF for protons p is given by the dose dependency Dp:
SFp = e
−αpDp−βpD2p (4.1)
For the test (reference) radiation x, the surviving fraction is given by:
SFx = e
−αxDx−βxD2x (4.2)
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The definition of RBE for an isoeffect1 (from International Commission on Radi-
ation Units and Measurements ICRU 2007) is:
RBE =
D(ref)
D
∣∣∣∣
effect
(4.3)
Where D and D(ref) are the doses required to produce the given effect, respec-
tively. Since the isoeffect is the same survival level, in this definition of RBE we
can therefore state:
SFx = SFp (4.4)
This equation is therefore solvable as follows:
⇒ e−αxDx−βxD2x = e−αpDp−βpD2p (4.5)
→ αxDx + βxD2x = αpDp + βpD2p (4.6)
Now making the substitution R = Dx/Dp (the isoeffect condition has already been
set in Eq.4.4):
αxRDp + βxR
2D2p = αpDp + βpD
2
p (4.7)
This can be readily solved as a quadratic in R:
R =
−αx ±
√
α2x + 4βx
(
αpDp + βpD2p
)
2βxDp
(4.8)
1Defined as a given biological outcome, held constant.
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To summarise the important aspects of the RBE Eq.(4.8), all terms are just
constants except for αp which varies such as αp = α0 + λL, and the non-physical
-ve result of this equation is ignored. Eq.(4.8) gives RBE as a function of dose from
protons. The tissue and endpoint dependence is given by the αx and βx values.
αp,βp depend on the LET (L) of the proton beam. αx,βx are known from the type
of test radiation at a specific energy.
The best fit for the model parameters as in the 2004 Wilkens and Oelfke paper
are shown in table 4.1 and also referenced by Paganetti in 2014. The reference
radiation is 60-Co gamma rays. In the 2004 Wilkens and Oelfke paper they also
take βp = βx. In the simplest models for monoenergetic beams, LET L = stopping
power S. In this 2004 Wilkens and Oelfke paper, LET is defined as a local mean
of the stopping power S, weighted by the local energy spectrum.
Therefore the dose depth dependence is known, then simply inputting the dose
value to Eq. (4.8) achieves the RBE-depth dependence, which can then be used to
produce biologically effective depth dose distributions. The required dose depth
dependence was discussed in chapter 2 of this thesis. However Frese et al 2011
deduced an average value for λ of 0.08µmkeV−1Gy−1.
Figure 4.1 shows the important graphical distribution inherent uncertainties in
the experimental data taken from the Wilkens and Oelfke, 2004 paper contributing
to some of the input parameter values of their overall model. The boundaries on
the other parameter values are found in the Tilly et al., 1999 paper. As seen in the
figure, the lines of best fit plotted are only rough approximations by inspection.
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Figure 4.1: Data for input parameters for the RBE model taken from the V79 Chinese
hamster cells with lines of best fit illustrated (Wilkens and Oelfke, 2004). Data for the
uncertainties for the αx and βx are found in the Tilly et al., 1999 paper.
4.2 Methodology
A one dimensional space was considered for the purposes of these simulations
and the EUD based NTCP model was the one used by Niemierko and Gay 2007
as discussed in chapter 3 of this thesis. A Monte Carlo approach was adopted in
order to try to quantify these uncertainties in terms of model output uncertainties.
For each input parameter to the model the program generates a random value
between that particular parameter’s minimum and maximum, as defined based on
the uncertainties from the sources of experimental data identified in this chapter.
As with Monte Carlo processes, many iterations are required and eventually there is
convergence on the combination of input parameters which produces the maximum
overall RBE at the point using Eq. (4.8) with a large number of iterations. The
landscape local maximum was therefore identified. Table 4.1 shows the collection
of uncertainties on the input parameters from the literature as discussed. For
consideration of the minimum values it can always be assumed that solutions
found are for the RBE value R > 1 and this sets the boundary by which lower
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values are not meaningful, this is because X-rays have an RBE of 1 and it is known
that protons have a greater biological effect.
Table 4.1: Table showing the experimental data based boundaries of the different
input parameters used in the Wilkens and Oelfke 2004 RBE model. The precisions
given are as found in the literature.
Parameter Value Lower Bound Upper Bound
α(p) α(0) + λL
α(0) 0.1Gy−1
λ 0.02µmkeV −1Gy−1
β(p) 0.0298Gy−2 0.01Gy−2 0.06Gy−2
α(x) 0.112Gy−1 0.067Gy−1 0.157Gy−1
β(x) 0.0298Gy−1 0.0249Gy−2 0.0347Gy−2
In the one dimensional grid modelling the lung tissue including the non-lung
tissue between both lungs, differing SOBPs and overflows were used in order to
calculate the increase in NTCP when the book values of RBE are compared to
the calculated maximum values. The following optimised proton beams were used
as the input to the model with clinicially useful widths of 6-10cm, 10-13cm, 14-
17cm, and 18-25cm. The spread out proton beams were also stepped back using a
simulated range shifter for each simulation in the one dimensional model with step
sizes of 1cm. Once the beam was simulated entering the lung depth the calculations
were performed based on the RBE using the quoted values from the literature and
the maximum value found from the program for biologically equivalent dose. Each
simulation is 60Gy representing 30 times 2Gy per fraction. In this way the increases
in resulting NTCP were found with calculations performed using the Emami et
al., 1991 and Marks et al., 2010 respective values of input parameters to the RBE
model.
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4.3 Results
Figure 4.2: A result from my Monte Carlo Optimizer program when run with a
10-13cm clinically flat region of SOBP. The flat line represents the physical depth
dose. The intermediate depth dose curve represents the RBE×physical depth
dose when calculated using the published parameter values which are contained in
Wilkens and Oelfke 2004. The largest depth dose represents when the results of my
program are plotted, finding the set of parameters for the RBE which maximises
the RBE×physical dose.
Mentioning the depth dose curve to begin with, figure 4.2 shows the result of my
Monte Carlo maximisation program when plotted for the RBE×Dose depth. The
lowest line in terms of dose shows the purely simulated physical dose where the dose
deposited for the user entered clinically useful region is 60Gy. The intermediate
curve shows the result for RBE×Dose depth when the quoted values from the paper
(Wilkens and Oelfke, 2004) for the input parameters to the model are used directly
without consideration of the uncertainties on them. As can be seen in both cases
where the effect of RBE was simulated, the peak at the distal end of the SOBP is
found as recognised in the review of relative biological effect papers in section 3.3
and furthermore in this particular case the maximum dose peak increases up to
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Figure 4.3: This figure shows the results of the simulated 4 RBE Emami et al.,
1991 parameters cases with my simulation setup as discussed in the methodology
section of this chapter. The increases in NTCP can be seen from observation of
the two data sets representing values with the maximised and non-maximised RBE
depth-doses.
90Gy at the distal end which demonstrates a maximum RBE found of 90/60=1.5
considerably higher in terms of percentage than the fixed clinical value of 1.1. This
falls into line with other literature as discussed in chapter 3 of this thesis which
postulates the RBE increasing at the distal end well beyond the clinically used
value of 1.1 for example the value of maximum RBE= 2.0 at the distal end of the
SOBP stated in Durante 2014. I have performed several other simulations in a
similar fashion to these three lines being determined, namely SOBPs of clinically
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Figure 4.4: This figure shows the results of the simulated 4 RBE Marks et al.,
2010 parameters cases with my simulation setup as discussed in the methodology
section of this chapter. The increases in NTCP can be seen from observation of
the two data sets representing values with the maximised and non-maximised RBE
depth-doses.
useful width 6-10cm, 14-17cm and 18-25cm.
Using the above versions of proton depth-dose curves which were plotted in
both maximised and published mean values of the parameters it was also possible
to perform the main part of my simulations on this topic as was outlined in the
methodology section of this chapter. Here the results of the aforementioned simu-
lations are shown in figures 4.3 and 4.4 are presented before the discussion of the
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general trends found.
Figures 4.3 and 4.4 are respectively split up into 4 graphs, each representing
my simulation results as described in the methodology section of this chapter for
different SOBP clinically useful widths. In each case, for each overflow in cm as
described by the use of the simulated range shifter the increases in NTCP can
be seen upon consideration of the black and red points plotted. The black points
show the set of parameters as presented without consideration of their associated
uncertainties when used in the simulations. Similarly, the red points show the set
of parameter values when the maximisation of the overall RBE has already been
performed, when also used in the EUD calculations within the simulated lung
region. It is possible to see by eye the shape of the curves formed by the respective
data sets as plotted.
For figure 4.3, in the case of the 6-10cm SOBP RBE variations Emami EUD
values at the top left hand side, it is found low overflows of 1 to 2cm cause very
low increases in NTCP ∼0 to 0.05. The greatest increase is found for the central
data points with overflows of 2.5 to 5cm with NTCP increases of up to 0.4. As the
overflow increases further, the difference between the book values and maximum
values calculation results decreases again as both values approach 1. In the top
right of the same graph, 10-13cm SOBP RBE variations Emami EUD values, it is
found that the sigmoidal shape is replicated but the differences between the two
curves is reduced. The maximum increase in NTCP is found to be ∼0.3 in the
central data point of 4cm overflow. In the bottom right for the 14-17cm SOBP RBE
variations Emami EUD, it is found again the same shape of the curves is replicated
but the difference is even less than the above cases. The largest difference is again
found at the central data point 4cm overflow corresponding to ∼0.3 increase in
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NTCP value. In the bottom right of the graph, for the 18-25cm SOBP RBE
variations Emami EUD, it is found that the difference between the two curves is
now increased and the maximum difference is found at the central point of 3.5cm
overflow of ∼0.5 difference in NTCP value. Again, the differences in NTCP values
reduce upon closer approach to NTCP values of 0 and 1.
For figure 4.4, in the case of the 6-10cm SOBP RBE variations Marks EUD
at the top left hand side, it is found that at 1cm overflow of the simulated SOBP
the value is 0 NTCP and there is no difference between the curves. At 6cm and
6.5cm overflow there is still a noticeable difference between the curves of ∼0.12
in NTCP value. The maximum difference is found at the central points at 4.5cm
overflow with a difference in NTCP value of ∼0.2. The top right of the same graph
shows the 10-13cm SOBP RBE variations Marks EUD. In this case, the general
shape of the curves appears similar but here the difference in NTCPs is less than
the directly previous 6-10cm case for the two curves, with the maximum difference
found here at 4.5cm overflow of a difference in NTCP value of ∼0.15. At ∼10cm
overflow there is still a noticeable difference between the curves of ∼0.1. In the
next case in the bottom right of the same graph, showing the 14-17cm SOBP RBE
variations Marks EUD, again the sigmoidal shape of the curves appears similar
but the difference between the curves is reduced compared to the directly previous
cases. Here at 1cm overflow and 12cm overflow respectively the NTCP values from
the two data sets (black and red points) are approximately in agreement with each
other. The maximum difference between the data sets is found here at the central
data points at ∼5.5cm overflow with a difference in NTCP value of ∼0.12. In the
bottom right of the same graph, this shows the 18-25cm SOBP RBE variations
Marks EUD case. This final case has a greater separation between the two curves
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compared to the other Marks graphs as previously for the 10-13cm and 14-17cm
cases. The shape of the curves formed by the respective data sets here remains
sigmoidal. The values are ∼0 NTCP value at 1cm overflow and start to approach
an NTCP value of 1 at ∼10cm overflow. In this case the largest difference is found
at ∼5cm overflow of ∼ 0.3 in NTCP value.
4.4 Discussion and Conclusions
Using the method described in this chapter, it has been found that from figure 4.3,
these results indicate that resulting RBE values have a large uncertainty and this
uncertainty shown above coupled with modern calculation methods can result in
NTCP increases of up to ∼ 50%. It is important to state that the method which
has been performed in this chapter has been a Monte Carlo based optimisation in
order to maximise the RBE at the point and therefore when the calculations were
performed the increase in NTCP based on the model assumptions are also at a
maximum. This does not provide a statistical distribution of the uncertainties so
it can be stated that the probability of all of the parameter uncertainties lining up
in such a way to produce this combinatory maximum RBE is not known.
These simulations have all been performed within the EUD model which is
only typically valid for large volumes of irradiation which by definition, as has
been seen in the literature in Gay and Niemierko 2007, are valid only for 1/3 of
the organ volume or larger. This study is also dependent on the uncertainties on
the LET, provided in the Wilkens and Oelfke, 2004 paper of 8.66% at 5cm. The
effects of uncertainty on the LET term has not been simulated here. In general it
has been found that when the more recent set of data for the input parameters as
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provided by the Marks et al., 2010 study this resulted in the simulations in a lower
increase in NTCP using the method as discussed, than when the simulations were
performed with the older Emami et al., 1991 parameter data sets.
4.5 Summary
RBE-NTCP models are quite simple but the inputs to these models remain rela-
tively uncertain2. I have performed an investigation based on studying the effects
of the previous statement. A one dimensional model of an adult male lung has
been constructed with dimensions as taken from Kramer et al., 2012. Four depth
dose spread out Bragg peaks have been used independently along with the use of
a simulated range shifter in order to control the dose overflow to the simulated
lung region, specifically clinically useful regions of 6-10cm, 10-13cm, 14-17cm and
18-25cm spread out Bragg peaks.
The use of the Wilkens and Oelfke RBE model as described in this chapter
has been included in the proton depth dose distributions and the functions of
RBE which depend on many different parameters has been investigated. This
investigation has involved the use of a Monte Carlo simulator that I have designed
which uses the uncertainties on the input parameters from the literature as has
been outlined in this chapter in order to calculate the local maximum RBE; that is
the combination of parameter values within their respective ranges which result in
the largest RBE value. Therefore in each case, both the quoted parameter values
resulting in the RBE without consideration of the uncertainties can be multiplied
by the physical dose distributions along with the use of the EUD based NTCP
2Personal commment from Tony Lomax, 2012.
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calulation method applied to the lung volume, and compare these final values
with the results of performing the same calculation but with the ‘maximised’ RBE
function. In this way an indication within my designed model can be found of the
resulting increases in NTCP purely based on the uncertainties associated with the
input parameters.
Trends of the resulting data sets have been examined and the maximum in-
crease in NTCP using the discussed method was for the Emami et al., 1991 input
parameters up to ∼50% and for the more recent Marks et al., 2010 parameters the
largest increase in NTCP found was lower than 30%. In general since this is the
absolute maximised difference on the uncertainties of the input parameters, this
may therefore be quite improbable, and one might expect clinically these effects
to be lower.
Chapter 5
Constructing the Lung Model and
Geometry
In order to accomplish the project goal, a lung model is needed in order to simulate
the effects of a physical dose overflow and perform the comparison between the
data based and calculation based methods in a wide variety of physical scenarios.
This is done not only for proton based simulations but also for X-rays. The idea
of a 3 dimensional geometrical model was inspired by Rutkowska et al., 2012.
This chapter introduces the methodology used for the main part of the project.
The respective methodologies for other areas, which have been studied within this
overall project, are discussed within other sections of this report including the
appendices. Overly detailed descriptions of the individual algorithms will not be
discussed in this chapter. The physics of the beam used and RBE effects are
discussed in other chapters.
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5.1 Modular Structure of Programming
The following introduces and explains the modular structure of programming nec-
essary, as shown in figures 5.1 and 5.2. The principle of having proton beams
requires knowledge of the underlying physical models which are discussed in chap-
ter 2. The * shown in figure 5.1 indicates that the physics models being used
in this project are based on work done by others, referenced where appropriate
and experimentally validated in the literature. Furthermore the three dimensional
spread of the beams is required to go from a one-dimensional model as found in
the literature to one suitable for use here; the way this has been done is also found
from the literature and is mentioned in this chapter. Moreover, the knowledge of
the RBE of proton beams was reviewed in chapter 3 and how to model this here is
included and was discussed in more detail in chapter 4. The “Lung Model” module
is discussed in detail in this chapter. The QUANTEC study was introduced also
in chapter 3 and the specific aspects of the Vx% probability based calculation are
also referred to in this chapter. The EUD based NTCP method being used has
been outlined in the literature review and specific aspects of implementing this
will be discussed later in this chapter.
Figure 5.1: Modular structure of programming for the lung fibrosis model and
additional considerations.
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Figure 5.2: Modular structure of programming for the reverse calculation and data
based method.
5.2 The Lung Model
A geometrical approach for constructing a lung model is used as inspired by
Rutkowska et al., 2012. Originally looking at the shape of human lungs, it was
found they resembled two cuboids with a spacing in between, at least as a 1st
approximation. It was therefore important to determine the accuracy of this ap-
proximation, and for that a benchmark was required and is discussed in Appendix
D. For accurately discerning the dimensions of these, the appropriate literature was
considered and was discussed in this thesis in chapter 3, specifically the Kramer
et al., 2012 paper to find the dimensions of the lung model. Following the dis-
cussion of the benchmark of the geometrical model (found in Appendix D) it was
found that the double cuboid model can be considered as a reasonable 1st order
approximation to a homogeneous structure of the lung.
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5.2.1 Geometrical 3D Model with Benchmark
In this section some technical detail will be described about constructing the lung
model. The appropriately sized 3 dimensional model of the lung is constructed
with the intention of storing a double (a type of data which is non-integer) in each
“voxel” of the construct which contained information about the dose deposited in
that voxel. I also wrote a program which, using this model, went through the entire
lung with a critical selection criteria: if the dose delivered to each voxel was above
the “critical dose” which is a user defined variable (for example a study using the
V5 metric means the critical dose is 5Gy) in the code then it incremented a defined
counter by 1 as a type of “boolean decision”. Therefore at the end the program
outputs the overall fraction of the lung which received at least the critical dose
for use in the linear averaging calculator to calculate the probability of inducing
a lung fibrosis effect based on the experimental data (with optional limits on the
extrapolation of the data sets). The idea of splitting up the overall large array into
smaller ones to avoid computational problems is described in section 5.2.2. The
space between the lungs, treated as water in the simulations, was readily omitted
when counting each of the voxels within the lung model across all sub-arrays needed
to calculate EUD within the two lungs.
How the program I wrote works is that it creates a single box array with
dimensions as shown in figure 5.3, where the voxel size was decided as the size
of an alveolus from the literature, as this was considered the size of 1 functional
sub-unit (FSU) of the lung, which is the minimum volume required to perform
a function of the organ; in the case of lung this function is to transfer oxygen
into the blood and remove carbon dioxide. Therefore going below this volume
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Figure 5.3: Graphical display of structure of the double cuboid lung model.
is unnecessary and a full voxelised picture of the lung has been realised. It can
be noted that As is the size of 1 cube of FSU along 1 axis (for an alveolus this
is a mean side length value of 0.208mm from the literature). Ochs et al., 2004
state that the number of alveoli is 170 per mm3 leading to a 0.208mm side length
assuming a uniform distribution and the Rutkowska et al., 2012 paper supports
the use of the single alveolus as the FSU.
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5.2.2 Lung Model Streaming
Declaring all the memory to store massive arrays for the lungs caused a stack
overflow1. A similar problem was found on the heap when I tried to consider the
entire lungs as one array at the lowest limit (taking 1 alveolus as 1 voxel or 1 FSU).
The computational method of “streaming” the data is graphically illustrated in
figure 5.4. This method allows any size array which must be considered using a
single computer’s random access memory (RAM) to be arbitrarily divided up into
smaller arrays to allow any sized array to be computed.
Figure 5.4: Structure of the double cuboid lung model as viewed by the program.
1The stack is the memory set aside as space for a thread of execution. The heap is memory
set aside for dynamic allocation.
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5.3 3-D Beam Overlay to the Lung Model
The proton pencil beams are always designed in my simulations to be entering the
lung volume at a plane face angle at the central point. The Gaussian formulation
of the spread of the beam (σ) given in the Bortfeld 1997 paper is included. This
method is explained in this section. Modern treatment planning systems used
in proton therapy assume entirely water as a starting point, and this is what is
included in this model. The method used is a 3D spread 1st approximation: σ ≈
σx ≈ σy, such that the respective beam spreads in either direction are symmetric.
σ2 = α′p2α
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Using the above Eq.(5.1) an array of σ values for each value of R0 can be
produced. p and α parameters are constants which are discussed in the original
1997 Bortfeld paper2; the main component of the equation is a range R0 depen-
dence, therefore different spreads for each respective Bragg peak. So in my model
the SOBP is decomposed into the original proton Bragg peaks and each of these
spread individually with the appropriate weighting factors. The dose calculation
model for 3D in my model is the same as the one used at the Paul Scherrer Institute
(PSI) and is described by Schaffner et al (1999):
D(x, y, z) = Np+ID(wer)
1
2piσxσy
e
− (x0−x)2
2σ2x e
− (y0−y)2
2σ2y (5.2)
Where ID(wer) is integral depth (water equivalent range). Np+ is simply a flux
term at the beginning of the equation (number of protons). As discussed the σx,y
2ICRU data gave p≈1.77 and α ≈ 2.2 × 10−3 for protons in water. α′ ≈ 0.087MeV2/cm for
water (Bortfeld, 1997).
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terms refer to the spread of the beam in each direction and the variables x0 and
y0 define the position of the entry point of the beam laterally. Therefore inputting
the approximation for σ into this dose calculation equation to achieve the new
equation for dose in (x,y,z) which was subsequently implemented into my model:
D(x, y, z) = Np+ID(wer)
1
2piσ2
e−
(x0−z)2
2σ2 e−
(y0−y)2
2σ2 (5.3)
Figure 5.5: Compound proton beam lateral divergence as it travels through the
simulated lung model, 3D spread.
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5.3.1 Lung Pencil Beams
In clinical proton therapy there is a painted dose with IMPT, resulting in the
possibility for many different pencil beams to be overflowing in the case of an
unwanted dose deposition to normal healthy tissue. Therefore the problem of
simulating multiple pencil beams was important to consider, otherwise the volumes
will be vanishingly small and non-realistic and non-useful; this problem is solved in
this section. In my simulation model the potential large number of proton beams
is modelled accordingly as explained in figure 5.6.
For the proton pencil beams, it is also possible to model having non-100%
coverage when the pencil beam model is scaled up to the entire lung, in other words
how many pencil beams overflow, assuming all of the lung behaves equally. For my
project I proposed the following set up: to study the effects of long range proton
beams not only on 3D adult sized lungs but also smaller sets of lung constructed
by the program, which could represent a child’s set of lungs for example. In this
way longer and shorter ranges of optimised proton beams including the effects of a
simulated range shifter will be simulated respectively, irradiating the constructed
volumes in order to produce critical fractions with suitable magnitudes of relevant
interest associated with the data investigations.
5.3.2 Vx% Counting Operation Using the QUANTEC Data
Set
As shown in figure 5.7, all of the different points within this graph from the QUAN-
TEC study (Bentzen et al., 2010) relate to different dose levels/indications/observations
and clinical data is non-existing below 10% of the lung. Therefore the focus for
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Figure 5.6: Properties of the pencil beam approach to a given volume and the
duplication (scaling) mechanism used as the individual beams are identical. The
pencil beams are initially 1D as in other areas of the literature but spread into 3D
within the simulated lung volume.
this project was drawn firstly toward study of the larger volumes of lung irradi-
ated above 10% where there is still data, before performing the extrapolation to
below this data range. The V40, V20, etc on figure 5.7 indicate the percentage of
lung receiving at least 40Gy, 20Gy, and so forth in this manner. Since incidence
of pneumonitis (%) is incidence of lung fibrosis, it is therefore possible to work
backwards using the dose-level and the percentage of lung irradiated to work out
the NTCP.
The methodology for this section of work I designed uses straight line connec-
tions between the points as a form of linear interpolation, provided from a pixel
analysis method (simply counting of the pixels with the appropriate scaling factor
for the units) to locate the co-ordinates of the original data points as shown in fig-
ure 5.7. The approach which was used in this project to improve the interpolation
of these data points (compared with the original lines shown on the graph) was to
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Figure 5.7: Original QUANTEC data set for the lung (Bentzen et al., 2010). The
method of locating the co-ordinates of the data points and the linear averaging
method of interpolation is described qualitatively in this section.
only perform the linear average across the respective ranges of validity but includ-
ing all of the relevant data sets for that metric, meaning staying within the upper
and lower boundaries of the individual QUANTEC data sets; for example in some
cases one or more data sets may be excluded when calculating the overall mean
value because it would mean extrapolating beyond the largest data value or in the
other direction below the lowest data value available. The different experimental
results shown in figure 5.7 were weighted equally as no mention of weighting fac-
tors was found in the QUANTEC study therefore the method of linear averaging
with the discussed boundary conditions was used in this module of programming.
Chapter 6
Results and Discussion
(QUANTEC and EUD) Data
Based and Calculation Based
6.1 Results Presentation and Discussion
6.1.1 Format of Results
Due to the non-linear response between calculated EUD values and resulting
NTCPs as shown in figure 6.1, it makes more sense to compare EUD values from
the different calculation methods. This is because, as shown in figure 6.1, a small
change in EUD will produce a larger difference in NTCP at the central regions in
the curve where the gradient is largest. So in order to do this, the ratio of EUD
values from calculation based to data based methods is defined as the parameter
‘k’ where, as this value approaches unity, a perfect agreement is seen. For k < 1
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Figure 6.1: This figure shows the (non-linear) sigmoidal curve response between
EUD value and resulting NTCP. Both axes are unitless.
the EUD value from calculation is lower and vice versa for k > 1.
Therefore the graphs showing the data results in this chapter are presented as
follows. Along the horizontal axis, the different metrics for study are plotted from
V5 to V40. Along the vertical axes, two parameters are plotted on the respective
axes, the k value and the critical fraction value - the fraction of the simulated lung
which receives at least the critical dose. The range shift (‘passive shift’) refers to
the simulation of a range shifter in front of the beam, acting to reduce the final
depth of the proton beam in the simulated medium.
How the error bars on the k values shown in the figures are calculated is pre-
sented in section 6.2 and this is of relevance for the study as it gives a measure
of the uncertainties on the results and therefore accuracy on conclusions which
can be discerned. Then in this chapter a description of what the plotted data
from figure 6.3 onwards is showing will be given, and following this the subsequent
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general trends which are found will be discussed.
While an EUD based model has been exclusively investigated, the old Emami
1991 paper parameters which go into this model are different from the Marks 2010
parameters so both paper parameters types have been investigated in this project.
6.2 Calculation of Error Bars for the Results
As shown in figure 5.7 there is a one-to-many function1 in terms of how the data
shows the particular Vx value relates to probability of lung fibrosis induction. This
is because in certain cases, but not all cases, there are multiple experiments on
the same metric leading to distinctly different results. So therefore for the data-
based module I needed to have a method for preferentially selecting to produce a
one-to-one function2 which can be meaningfully used. The method I chose was a
linear average within the limits of acceptibility of the data range and this will be
discussed in this section.
The errors are fundamentally calculated by the spread of the available data
(different experiments) as shown in figure 6.2. While the individual data points
are disconnected, the program I wrote to compute the errors calculates the gradi-
ents between them and performs the interpolation to find a result across all valid
ranges, with the extrapolated data outside of the available range not included in
the linear average to improve accuracy. Since there is no mention of weighting fac-
tors from the original QUANTEC paper for lungs, a linear average method cannot
be improved on by adding weighting factors.
1A function y1 = f1(x) where inputting the same x value does not always return the same y1
value
2A function y2 = f2(x) where inputting the same x value always returns the same y2 value
6.2. CALCULATION OF ERROR BARS FOR THE RESULTS 96
Figure 6.2: Example of how the program for calculating errors interpolates the
QUANTEC data between the data points.
The linear average of the probabilities can produce different results depending
on which data sources are selected. It was therefore possible using the program
I wrote to go through the existing data tables to determine error bars by looking
at the difference between the maximum and minimum predictions between the
differing QUANTEC sources. In the cases where there are no multiple data sets for
a given metric, this method cannot be applied to produce maximum and minimum
values since there is only one input value. There was a backwards calculation which
enabled the data equivalent EUD values to be calculated from the linear average
probabilities and the k values as well.
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6.3 Presentation of Data Results
In this section there is a presentation of what the raw plotted data results I have
found are showing. The next section will present the general trends (a summary)
which can be concluded from these raw data. The results in this section are
grouped by lung size simulated and shown in the figures in units of cm. Adult
lung refers to 12cm width with 7cm spacing between lungs and small lung refers
to 7cm width with 2cm spacing. The third dimension is also shown in the figures
but is of less relevance due to the pencil beam model being used.
6.3.1 Adult Sized Lung Simulations
Figure 6.3 shows the results for the case of Emami parameters, adult sized lung,
6-10SOBP (6-10cm clinically useful region). This graph shows that for the 0cm
passive shift of the proton beam most values of k ∼1.6 show a flat distribution,
with critical fractions from 0.6 to 0.1. As the passive shift increases, the resulting
k increases: at 4cm shift k ∼2.3, 1cm k ∼1.8, 2cm k ∼1.9. It is found critical
fractions decrease with increasing Vx metric, with lower critical fraction values for
larger passive shifts. A good indication of typical sizes of the errors found on the
k values within this set of data are as shown in the 2cm passive shift case for the
V20 metric with the range k ∼1.6 to 2.3.
Figure 6.4 shows the results for the case of Marks parameters, 10-13cm SOBP
and adult sized lungs. Without errors the k values have value ∼2.0, but with
the inclusion of errors the lower bound of k reduces significantly. There is an
approximately flat k distribution as shown including passive shifts. The critical
fractions here range from 0.4 to 0.01. Critical fractions here reduce with increasing
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Figure 6.3: This figure shows the 4 passive shift cases for the EUD Emami param-
eters comparison for adult lung irradiation with a proton beam SOBP of clinically
useful width 6-10cm.
passive shift, with the 4cm shift case showing the critical fractions decreasing from
∼0.3 to 0.03. In this case, the errors can be large - for the 1cm passive shift V20
metric the k values including error bars show a range from ∼0.8 to 2.2.
Figure 6.5 shows the results for the case of Emami adult 10-13cm SOBP and
adult size lungs. It is found that the critical fractions steadily decrease from ∼0.6
to 0.1 across increasing Vx metrics for all cases with the exception of the 4cm
passive shift where the V5 metric result shows a larger critical fraction value. For
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Figure 6.4: This figure shows the 4 passive shift cases for the EUD Marks param-
eters comparison for adult lung irradiation with a proton beam SOBP of clinically
useful width 10-13cm.
the 0cm passive shift case, the k distribution is approximately flat with k from
1.7 to 0.9 including errors. As the passive shift increases, the distribution of the
k values remains approximately flat. For the 4cm passive shift case the k values
range from 2.0 to 1.2 including errors, and the critical fraction values remain
approximately the same. Typical error sizes are as in the 0cm passive shift case
for the V30 metric showing the range of k values of ∼0.9 to 1.5.
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Figure 6.5: This figure shows the 4 passive shift cases for the EUD Emami param-
eters comparison for adult lung irradiation with a proton beam SOBP of clinically
useful width 10-13cm.
6.3.2 Small Sized Lung Simulations
Figure 6.6 shows the results for the case of Marks parameters, small lungs (7cm
width, 2cm spacing), and 10-14SOBP (10-14cm clinically useful region). This 0cm
passive shift case shows a smooth decline in k values from 1.8 to 0.9, and critical
fractions from 0.9 to 0.1. Adding the passive shift changes the distribution of
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Figure 6.6: This figure shows the 4 passive shift cases for the EUD Marks param-
eters comparison for small lung irradiation with a proton beam SOBP of clinically
useful width 10-14cm.
values; for a 4cm passive shift in the directly previous case, the k values become
approximately flat k ∼1.5 with the critical fractions decreasing from 0.6 to 0.05.
Large error bars are found here where multiple data sources are available: here in
the case of the V30 metric a difference in k is found from 0.6 to 1.4 for the 0cm
passive shift case.
Figure 6.7 shows the results for the case of Emami 10-14cm SOBP and small
lungs. It is found for the 0cm passive case, the k values distribution is approxi-
mately flat with k values ranging from ∼1.5 to 0.9 with associated critical frac-
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Figure 6.7: This figure shows the 4 passive shift cases for the EUD Emami param-
eters comparison for small lung irradiation with a proton beam SOBP of clinically
useful width 10-14cm.
tions steadily decreasing from 0.8 to 0.1. As the passive shift is increased, the
distribution of k values remains approximately flat with critical fractions reducing
particularly for the 5Gy metric. Typical error sizes on the 2cm passive shift case
are shown for the V30 metric showing a k value ranging with errors from ∼1.1 to
1.4.
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Figure 6.8: This figure shows the results from the 1-D or ‘step-function spread’
proton beam cases for the shorter range beam 6-10cm and the longer range beam
10-13cm for adult sized lungs.
6.3.3 One Dimensional/Step-Function Spread Simulations
For the 1 dimensional (or step-function spread) proton beam cases, the results for
the shorter and longer range proton beams are shown in figure 6.8. The case on
the left hand side of this figure shows the 1D proton beam case (both adult lungs
cases) 6-10cm SOBP, critical fractions ∼0.4, and k values ranging from 1.8 to 0.9.
The critical fractions shown here are approximately flat. The k values showing
values of ∼0.9 are similar for the V5 and V13 metrics with 2 outliers at the V25
metric respectively. The second case on the right hand size of this figure shows
the 1D proton beam case (adult sized lungs) 10-13cm SOBP. The k values shown
range from 1.5 to 1.0. The k values are approximately flat within this range across
the Vx metrics. In this case the critical fractions are also approximately flat across
the Vx metrics with value of ∼0.5, with the exception of the V40 metric which
has a value of ∼0.2.
For the 1 dimensional x-ray irradiation case for 30% of the plane face irradi-
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Figure 6.9: This figure shows the comparison of results from Emami and Marks
parameters for X-ray irradiation case for 30% of the plane face volume for adult
sized lungs.
ated, shown in figure 6.9, the k values respectively for both Marks and Emami
parameters are ∼flat with an outlier in both cases at the 25Gy metric. Emami
parameters k ∼1.1, Marks parameters k ∼1.0. The distribution of critical frac-
tions is ∼flat and has value ∼0.3. Here it is found the majority of data points
for the k values are approximately within 20% of unity, showing a relatively close
agreement when compared to the overall body of results found for protons.
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6.4 General Trends Found
6.4.1 General Trends for Results from 1D/Step-Function
Beam Spread
In both of the 1D proton cases, adult sized lung were simulated (6-10cm, 10-
13cm respectively clinically useful region sized proton SOBPs). Here, generally
the critical fraction3 remains approximately flat in both respective cases except for
the V40 in the 10-13cm SOBP case which displays a noticably lower value. In the
case of the lower range SOBP, the V5 and V13 metrics for both EUD calculation
results with Emami and Marks parameters respectively show k values quite close
to unity, within the range 0.8< k <1 showing a good agreement between the data
based and calculation based methods.
A similar scenario is found for the longer range proton beam scenario in the
above case. Here the results for the V5 and V13 metrics both show k values
which are within the range 0.9< k <1.1 again showing a close agreement, leading
to the conclusion that the 1D simulation results with protons are showing for the
V5/13 metrics at the 40%-50% volume level, the QUANTEC data based and EUD
calculation based methods are suitable. In the above cases, the larger dose metrics
for the Vx values show less agreement, with the values ranging from 1.1< k <1.3
at the V40 metric for the 10-13cm range SOBP. So a general conclusion which can
be drawn from this study is that while certain cases show good agreement others
do not and careful consideration must be given before employing either method as
stated in the original QUANTEC paper (Bentzen et al., 2010).
3The amount of simulated lung which receives at least that dose.
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For the step-function X-ray result shown in figure 6.9 with 30% plane coverage
irradiated, it is found that the distribution of k values are approximately flat with
an outlier in both cases at the 25Gy metric. Disregarding the outlier at the V25
metric and considering the rest of the values at V5, V13, V20 and V30 it is found
all of the scaling factors (k values) are within the range 0.8 < k < 1.2 therefore
showing a good agreement for the X-ray data results in general. On average it
is found Emami k ∼1.1, Marks k ∼1.0. The distribution of critical fractions is
approximately flat across the metrics and has value approximately 0.55.
6.4.2 General Trends for Results from Gaussians Beam
Spread Functions
In general for the proton studies with Gaussian spread functions, as shown in
figures 6.3 to 6.7, the critical fractions all decrease with increasing Vx value, which
is understandable because the critical dose value is higher; the decrease tends to
follow a smooth curve for all cases presented.
A general conclusion which can be found across the majority of data produced
is that within the individual studies, the k values maintain an approximately flat
distribution across the metrics V5 to V40. The passive shift which models the use
of a range shifter acts to bring the beam back reducing the fraction of the lung
which receives at least the critical dose but when this was done, not in all cases
did the results show a correlation with overall increased k values.
From the available results, it is hard to conclude that one metric is better
overall than another. There is no evidence in all cases to show for example that
V20 or V25 is consistently better. For the first and second data sets listed in this
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chapter V20 provides the best agreement but only for the first two passive shift
cases in the Emami adult lungs study shown in figure 6.3 and first three passive
shift cases for the Marks small lungs shown in figure F.6. For the third set shown
as in figure 6.4, V20 is not the best agreement and this is also true in figure 6.5
where the V30 metric is providing the best agreement within the set of data results.
In the final set shown in figure 6.7 the V20 metric provides the best agreement
but only for the first 3 passive shift cases. There seems to be no preference to the
Marks parameters values to justify this hypothesis.
Considering here the data points below and above 1/3 of the total volume. In
the first data set shown in this chapter in figure 6.34 it is generally not seen that
there is an increase or decrease in agreement (k values closer to or farther away
from unity). In the second set of data shown in figure 6.6 overall there is a greater
vertical spread of data points including errors and similarly results from both
above and below the 1/3 of total volume mark show it is in general not possible to
conclude a better or worse agreement for >1/3 or <1/3 total organ volume. The
same final conclusion is true for the remainder of the data presented here as well.
There are not enough data points in the non-Gaussian spread functions to make
a similar conclusion.
6.5 Summary and Discussion
In general the majority of scaling values for the EUD factors (k values) have had
values ≥1. However there were also values found which were k < 1 as mentioned
below. Therefore showing the conclusive trend that there is not a definite system-
4Showing both data from above and below 1/3 of the total organ volume.
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atic preference to either calculation or data based interpolation given the data set
used to either a higher or lower value in general. The k values provide an intrinsic
tool to examine percentage difference between the two methods as a k value of 1.1
indicates a deviation of 10% between the compared EUD values, which in turn be-
comes scaled in the non-linear curve shown in figure 6.1 to a resulting probability
of normal tissue complication.
To summarise, the data generated does not support the claim that the V20 or
V25 are the best agreeing metrics necessarily. This is displayed in figures 6.4 and
6.5 where these two metrics do not provide the best agreement within the data
sets respectively. Overall the results seem to show no increased disagreement when
the critical fraction (volumes) < 1/3 total volume are examined, moving outside
the validity range of the EUD model. So the agreement at the higher volumes
performed in the validation section is therefore not disrupted as the regions below
1/3 of the total organ volume are examined.
The ranges of the data which have been presented in this chapter give an idea
of where the data is contained and give upper and lower bounds on the ratios and
therefore accuracy of agreement in results. The data ranges have been found aross
all of the individual studies. For the X-ray results all the data points are within
the range 0.8 < k < 1.8 with the majority of the data points within the range
0.8 < k < 1.2. Figure 6.5 shows 0.8 < k < 1.8 for the majority of the data with
the exception of the V5 k value for the 4cm shift. The Marks adult lung case
shown in figure 6.4 tends to show larger k values > 2 but the error bars on this
graph set low boundaries for the k values down to ∼ 0.8.
In the Emami 6-10cm SOBP adult lung case the majority of the k values data
points are for the 0cm shift around the k ∼ 1.6 mark with the upper bound
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including errors up to k ∼ 2.1 and lower bound down to k ∼ 1.0. This range
systematically increases with increasing passive shift up to the 4cm range shift
case where the majority of the data points are around k ∼ 2.2 with the upper
bound k ∼ 2.5 and lower bound k ∼ 1.8 including error bars.
In the case of the Marks parameters small lung with 10-14cm range beam
(with Gaussian spread) to produce larger critical fractions for study (produced up
to ∼ 0.8 and ∼ 0.1) the data shows k values for the 0cm passive shift ranging
from 0.55 < k < 1.8 for all k values. For greater passive shifts the large error bars
define the range maximally at the 4cm shift case 0.8 < k < 2.6.
The case of EUD parameters small lung with 10-14cm SOBP (with Gaussian
spread) to produce larger critical fractions for study, produced up to ∼ 0.85 and
down to ∼ 0.07. The data points seem relatively closely grouped together and
seem close to unity - for the 0cm shift case, including errors all the data points fall
within the range 0.8 < k < 1.4. As the passive shifts increase, the relatively close
bunching of the data still remains and so does the proximity to k = 1 compared
to the other studies. In the 1cm passive shift case the data is contained within
the range 0.85 < k < 1.7 including errors again seemingly closely bounded, and
finally for the 4cm shift the k values seem to increase 1.2 < k < 2.0 however the
closeness of the data points to each other still remains in a flat distribution.
In the one dimensional/step-function spread proton cases, displayed in figure
6.8, both looking at adult sized lungs irradiation simulation, for both the shorter
6-10cm and 10-13cm range SOBP it appears there may be too few data points
generated to justify writing boundary/range trends as with the previous cases.
Referring to the previous description of this data set seems to provide an adequate
description contained within this chapter.
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In the one dimensional/step-function spread X-ray case, displayed in the figure
6.9, the k values from the Emami parameters are contained within the range
1.0 < k < 1.5 with an approximately flat distribution across the Vx metrics. The
same shape of the distribution applies for the k values with the Marks parameters
as well including the seemingly outlier point at the V25 metric. The range is given
here by 0.8 < k < 1.8 with values of k < 1 for both the V5 and V20 metrics in
this case, thus displaying the conclusion that the EUD calculation based method
does not always produce greater EUD values (and hence probabilities) than the
alternative data based method which has been investigated in this project.
Though widely used and discussed in the literature Vx may not be a very
good variable to characterise the dose distribution because it cannot distinguish
between a uniform dose distribution and one with a very large dose spike at the
end for example. This may be of particular relevance as the protons beams which
have been used within this simulation model have had an analytical RBE model
included which typically acts to increase the dose at the distal end of the spread out
Bragg peak (Wilkens and Oelfke, 2004). Comparing the results from the smaller
lung coverage simulations with the results from large (adult sized) lungs coverage
as in table 6.1, it is found that for the small sized lungs the use of the EUD
may be more appropriate, producing lower k values and more agreement between
the EUD method and data-based method. This is because the dose is uniformly
covering the volume in question and therefore we expected more of an agreement
rather than the larger adult lung simulation results with a smaller range beam
where often the second lung receives zero dose and the EUD calculation model is
approximating a uniform dose distributed. However, despite its drawbacks this is
the model which is widely used in clinical NTCP modelling and hence why it was
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chosen for investigation.
Table 6.1: Sorted table comparing the different average k values (< k >) for 0cm
range shifts in the different cases.
Parameters Size of Lungs Size of SOBP (cm) < k >
Marks Adult 10-13 ∼ 2.0
Emami Adult 6-10 ∼ 1.6
Emami Adult 10-13 ∼ 1.3
Marks Small 10-14 ∼ 1.2
Emami Small 10-14 ∼ 1.1
Regarding the ranges of the k values which are plotted, upper and lower limits
on agreement or disagreement between the two methods have been found, giving
a measure of accuracy of data (available spread) and therefore an indication of
the accuracy with which conclusions can be drawn and are discussed; it can agree
very well but there is a large variance found on the results (spread of k values).
However there is also a large degree of uncertainty on the EUD model, which is
being used widely, and a large degree of uncertainties on the QUANTEC data (in
that study, the goal was to assimilate all available data for NTCP response - not
an easy task). An improved quantification of errors as well as proton data would
help improve accuracy however the data found has shown there is no reason to
rule out the method developed and investigated in this report, particularly using
the data based method on 1/3 of the total organ volume or less.
It is expected that using the method within this study, the lack of proton data
could improve accuracy since all the results here have been found from mapping
proton irradiations to X-ray results. However due to this fact, X-ray irradiations
were also studied within this project. From the results that have been obtained in
this project, it is reasonable to suggest the approach could be used at less than 10
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percent of the organ volume where the EUD method is not applicable.
A measure of error bars on the values has been plotted from the max/min
method discused earlier in this chapter in section 6.2, leading to sometimes large
error bars in certain cases. However using this method alone there are sometimes
no error bars for certain metrics: V5 and V25 always have no error bars because
there is only one source of data so the method outlined in section 6.2 cannot be
applied. However while no error bars are shown on the graphs for these metrics,
because there is only one source of data for these metrics, the real uncertainties
on them may be much larger. In general, there are much greater sources of un-
certainties within the simulations which are not listed in the method described
in section 6.2, for example the lack of a use of a density heterogeneity correction
which is also not present in modern treatment planning systems, which leads to
the field of robust analysis for proton irradiations. Therefore relying on some of
the accurate boundaries acheived for the ratio k values (ratio factors) between the
two methods may also present additional uncertainties from other sources.
To compare the metrics from the older and newer studies between the Marks
and Emami parameters both used in the EUD calculations (Marks et al., 2010,
Emami et al., 1991). The ranges for the k values found provide a basis for tentative
conclusions, i.e. not always k ≥1, providing the important non-systematic conclu-
sion between the calculation types. Although there are other models in existence
the EUD one is still the most widely used and so has the most relevance for this
study, which is why the most focus has been applied on it. Across all of the ‘k’
ratio values obtained, and shown in the graphs, these have always been simulated
for a total dose of 60Gy after 30 fractions of 2Gy per fraction, providing simulation
of a typical radiotherapy course for the patient.
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A verification between large volumes for the two methods is shown in Appendix
E. Overall, and generally, this project has allowed the analytical simulation of a
large range of setups resulting in the generation of a large range of data points.
This is particularly important as it allows a quantification of a particular physical
dose overflow (e.g. how the results from a 2cm dose overflow behave) without prior
knowledge of the physical volume receiving a certain dose.
Chapter 7
Conclusions
7.1 Summary and Project Questions Answered
With the development of proton therapy in the UK and worldwide, more research
is required on the biological effect. A knowledge of how well the novel data based
method, which has been introduced, can perform has been investigated. This
thesis has explored a number of areas of investigation relevant to modern proton
therapy issues. This is important for the future optimisation of cancer treatment.
In chapter 1 of this thesis, a broad overview of proton therapy was presented
and the project’s research questions were outlined. How well does a data based
replacement agree with the EUD model at large volumes and can the data based
approach therefore be used to make predictions where the EUD model is no longer
valid at <1/3rd of the total organ volume or <10% where there is no experimental
data, and how accurate do we expect these predictions to be? This question has
formed the basis of the main project which has been investigated. Multiple data
sets have been presented and discussed in chapter 6. A sensitivity analysis of
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the gradient of the NTCP-EUD curve has been conducted in section 6.1.1 and
a validation of the model has been discussed in Appendix E. A quantification
on the errors involved with making predictions using the various experimental
results within the QUANTEC data sets has been discussed in section 6.2. This
allows error bars to be meaningfully plotted on the graphs containing the data.
However, naturally in this modelling project there were other sources of error
involved that have therefore provided the incentive for attempts to benchmark the
overall model approach used, such as the one found in Appendix D - Benchmark
of the Geometrical Lung Model. The various data sets which are presented in the
QUANTEC study for lung are weighted within their respective ranges of validity
as a mean value of the contributions, and the mechanism I wrote employed to
perform the interpolation to below the region where there is existing data (and
above) is explained qualitatively at the end of section 5.3.2. The simulation of
X-ray irradiations was performed in this study using the theory of dose deposition
as explained and referenced in section 2.4. Where X-ray irradiations are modelled
instead of proton beams the influence of varying proton beam setup configurations
on the results has been studied. The results which have been found using the
X-ray simulations are displayed in section 6.3.3. The k values which were found
in the X-ray study were relatively good, with an average value of ∼1.1 (meaning
a 10% percent difference in the ratio between EUD values from the data based
and calculation based methods respectively) across both Emami and Marks data
sets, the data found ranging from ∼0.9 to a maximum k value of ∼1.7 as shown
in figure 6.9.
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7.2 Main Project Investigated Conclusions
In this section the conclusive arguments for the main part of this project will be
presented, repeating some of the key results found where necessary. Although
there are other models, the EUD one is still the most widely used and so has the
most relevance for this study. The k values were used to quantify the ratios of
agreement due to the non linear response of the NTCP values to the EUD inputs as
discussed in section 6.1, because the EUD calculation method is more susceptibile
to uncertainties at the middle range of the EUD values where the gradient of the
curve is largest as shown in the graph NTCP vs EUD as in figure 6.1. The inclusion
of the errors discussed in section 6.2 as calculated acts to extend the upper and
lower bounds of the range of the results which are obtained for a given simulation
set. For the results found in this project, in certain cases due to the existing
data set ranges, the error bars are only in one direction or where there is only
one data set available it is not possible to employ the method outlined in section
6.2. The inclusion of additional unknown sources of error which are present in the
simulations would act to widen the error bars as displayed in the results graphs in
chapter 6, not to reduce them.
A large body of critical fractions have been examined, which are naturally lower
with the Gaussian spread functions than with the 1D proton step functions, both
above and below 1/3rd of the total organ volume, as plotted in the second vertical
axes shown in the graphs of chapter 6 of this thesis. For the studies performed with
the Gaussian spread proton beams, this study has found that it is not reasonable
to definitively conclude that one metric (Vx) performs better than another across
all of the data obtained. In the Emami adult lung study using a SOBP of clinically
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useful width of 6-10cm using proton beams which were spread by means of a double
Gaussian, V20 was found to provide the best agreement, but only for the first two
passive shift cases (0cm range shift and 1cm range shift). Across all of the results
which have been obtained in this project, there is no evidence in all cases to show
that V20 or V25 is consistently better.
A general conclusion which can be drawn is that for the proton studies while
certain cases show good agreement others do not and careful consideration must
be given before employing either method. This conclusion is also stated in the
original QUANTEC study (Bentzen et al., 2010). In the step function spread case
for protons, using a simulation of adult lung irradiation, with a 6-10cm clinically
useful region SOBP used, the V5 and V13 metrics for both EUD calculation results
with Emami and Marks parameters respectively, show k values quite close to unity
within the range of 0.8< k <0.1 showing a relatively good agreement between the
data based and calculation based methods. Furthermore in the 10-13cm SOBP
clinically useful region case with the same setup, the k values for the metrics V5
and V13 both show values between the range 0.9< k <1.1 at the 40-50% volume
level.
This project has found there was no increased disagreement between the two
methods examined when volumes below the 1/3rd of the total organ were studied,
as shown in figure 6.3. Let us mention the example of the V40 metric result
for the Emami parameters study of the adult lung using a SOBP of clinically
useful width 10-13cm: here the raw k value was found to be ∼ 1.15 at a volume
level of ∼15%. This provides evidence to state that since a good agreement in
certain cases between the methods has been found at higher volumes, a definitive
reason to discount the predictive power of the data based method at volumes <1/3
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(including the interpolation of the data series to below 10% of the organ volume)
as a replacement for the EUD model has not been found at lower volumes.
An attempt to condense the overall body of results found for proton studies to a
simple comparison is shown in table 6.1. The table shows that a better agreement
was found when the small simulated lung with long range proton beams were
studied; this makes sense within the understanding of the EUD model as it is
approximating the entire delivered dose distribution as a uniform dose. Keeping
the preferential agreement shown in table 6.1 to the longer range beams used with
the smaller simulated lungs in mind, for lower range proton beam investigations
with adult sized lungs for simulation, k values close to unity were also found; in
the volume range studied between 40-50% for the adult sized lungs and a 10-13cm
SOBP used for the V5 and V13 metrics the k values which are found are relatively
close to unity, less than a 20% difference when the respective EUD values are
compared in a ratio.
To reiterate, the future availability of proton data could improve accuracy since
all the results here have been found from mapping proton irradiations to X-ray
results. However due to this fact, X-ray irradiations were also studied within this
project. From the results that have been obtained in this project, it is reasonable
to suggest the approach can be used at less than 10 percent of the organ volume
where the EUD method is not applicable. Furthermore, to recap, the data ranges
have been found across all of the individual studies. For the X-ray results all the
data points are within the range 0.8 < k < 1.8 with the majority of the data points
existing within the range 0.8 < k < 1.2.
The data-based method which was used is clearly subject to error, as the differ-
ent respective experimental data sets which were compiled will produce dramati-
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cally different results. However, the popular EUD method is also clearly subject to
effects of uncertainties as well; for the lung, small errors in uncertainties in calcu-
lated EUD can produce dramatically different NTCP values due to the high power
term in Eq.(3.2). In agreement with the existing literature, this study suggests
that in any case an ALARP principle (As Low As Reasonably Practical) should be
adopted to avoid irradiation wherever possible since there is no benefit of receiving
radiation to normal healthy tissue. This is being done in modern radiotherapy and
proton therapy with robust analysis which acts to quantify the sensitivity of plans
to all forms of uncertainties in an effort to reduce the overall potential negative
effects incurred for the patients when the uncertainties are in action. Generally
speaking it is possible to conclude that the more dose which is delivered to the
lung the more likely it is under fixed conditions (other variables remaining the
same) that RP will be induced; a statement found in all of the experimental data
including data sets such as QUANTEC.
While the majority of the scaling values for the EUD factors (k values) found
have been ≥1, an important non-systematic conclusion has been found during this
study, in that not all determined k values were greater than 1, yielding no system-
atic preference to either the calculation based or data based methods respectively.
Upon examining the available literature it is clear that due to the complexity
of the subject matter it can be prudent to define thresholds on the metrics in
question which are available for NTCP modelling. Marks et al., 2010 conclude that
it is challenging because there are no clear thresholds for candidate metrics, the
response function is often gradual and the acceptable risk varies with the clinical
scenario. The authors then state that despite these caveats, it is prudent to limit
V20 to ≤ 30− 35% for conventional fractionation if the risk of inducing RP is to
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be limited to ≤ 20%, in definitively treated patients with NSCLC. The authors
further state that in patients treated post-pneumonectomy for mesothelioma, it is
prudent to limit the V5< 60%, the V20< 4−10% and the MLD< 8Gy. Matsuo et
al., 2012 recalls the conclusion of the QUANTEC study for lung which produced
the following guidelines: recommending a V20 of ≤30-35% and MLD of ≤20-23Gy
to limit the risk of RP to ≤20%.
The literature also suggests there may be a serious issue in the commonplace
condensation of the 3 dimensional dose distribution to a single scalar value (as is
done in all of the NTCP modelling methods I have examined). Bentzen et al.,
2010 summarise this by saying that generally, NTCP models attempt to reduce
complicated dosimetric and anatomic information to a single risk measure (i.e.
going from a 3D map to a probability).
EUD is a widely used method because it gives a way of putting a biological
effect to dose1. It was also stated that individuals are very different so it may
not be possible to replace the EUD calculation method. The QUANTEC paper
(Bentzen et al., 2010) also identifies the problem in NTCP modelling of obtaining
a good degree of accuracy. Presently, it is important that critical discussions
and investigations such as the ones within this thesis on this topic exist within
the overall body of literature. NTCP modelling is still in the early stages of
development and slow progress is expected without major revolutions2. As stated
by Appelt et al., 2014, prediction of the risk of RP for individual patients is still
fraught with uncertainties, and this may be part of the reason for the limited
1Personal comment from Tony Lomax, Advanced Radiotherapy Summer School, Christie
Hospital 2016.
2Personal comment from Norman Kirkby, Advanced Radiotherapy Summer School, Christie
Hospital, 2016.
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predictive power of even the best published models.
7.3 Future Work
The use of proton data to match to proton irradiations, where existing, would
potentially help to improve the agreement between the two methods investigated.
The effects of physical dose overflows and their outcomes have been investigated
within the simulation model as designed in this thesis, a study of which physi-
cal dose outcomes produce different outcomes for the simulated patient could be
additionally investigated. A simulation of X-ray based irradiation has been inves-
tigated in this thesis within the simulation model designed, however to improve
this the use of a multi-field optimiser could be included to better reflect the flat
dose regions which are the endpoint goal of conventional X-ray radiotherapy. Cur-
rent treatment planning systems do not take into account density inhomogeneities,
this concept could be investigated further within the lung tissue simulated. The
concept of the use of a phantom or real patient data would not act to improve the
range of proton dose and X-ray dose set ups which have been simulated in this
project to generate fixed dose overflows, creating critical fractions of dose received
in the lung tissue, however, a statistical compilation (a demographic) of dose over-
flow received may be useful to investigate from a clinical point of view. The same
study performed in this thesis could in principle be performed for other organs in-
cluding multiple (different) organs at risk. The technique of using an initially one
dimensional beam for simulations has been seen to be used in existing literature
(Symonofsky and Oefkle, 2002) and this has been adopted here. However, while
used elsewhere, instead of spreading 1-D beams into 3 dimensions a more realistic
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approach would be to consider a beam of fixed width and then spread it as the
beam travels through the medium in 3D.
Appendix A
The Bethe Bloch Model
The entire Bethe Bloch model is not discussed but instead only the aspects of
the model which are relevant to proton therapy; stopping power at intermediate
energies. The mean rate of energy loss by moderately relativistic charged heavy
particles is well-described by the “Bethe-Bloch” equation, which should be used in
this appendix along with the reference provided from (Nakamura et al., K, 2010)
for a full understanding of the following:
−
〈
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〉
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− β2 − δ(βγ)
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ρ (A.1)
The relevant symbols used in this equation are defined as follows. δ(βγ) -
Density effect correction due to the ionization energy loss. E - Incident energy.
T - Kinetic energy. γ - relativistic gamma factor. c - speed of light. I - Mean
excitation energy. me - mass of electron. β = v/c velocity as a fraction of the
speed of light. ρ - material density. NA - Avagadro’s number. re - classical electron
radius. A - Atomic mass of absorber. K/A - 4piNAr
2
emec
2/A. M - Incident particle
mass. mµ - Mass of the muon. Z - atomic number of absorber.
This equation has been described at a conference I attended as the most fre-
quently used and poorly understood in the whole field of charged particle interac-
tions! It describes the mean rate of energy loss in the region 0.05 < βγ < 500 and
M > mµ. The ρ term is added from a lecture series I found given in Heidelberg
which makes this equation dimensionally correct, otherwise we are simply talking
about MeV cm2/g which is also correct. For 0.01 < β < 0.05 there is no satis-
factory theory. It is valid for intermediate-Z materials with an accuracy of a few
%.
Particle Data Group (PDG) states that the Bethe Bloch equation may be
integrated to find the total (or partial) “continuous slowing- down approximation”
(CSDA) range R for a particle which loses energy only through ionization and
atomic excitation. Since dE/dx depends only on β, R/M is a function of E/M or
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pc/M . In practice, range is a useful concept only for low-energy hadrons (R < λI
, where λI is the nuclear interaction length), and for muons below a few hundred
GeV (above which radiative effects dominate).
This integral method described is made possible by the form of Tmax = Tmax (β, γ) =
2mec
2β2γ2/
(
1 + 2γme
M
+
(
me
M
)2)
as this value only depends on β, γ and other con-
stants. While the other terms in Eq. A.1 are standard, the mean excitation poten-
tial I and delta correction term δ (βγ) are of particular interest when considering
how accurate this model can be. The density effect correction is usually computed
using Sternheimers parameterization:
δ (βγ) =

2(ln10)x− C¯ if x ≥ x1
2(ln10)x− C¯ + a(x1 − x)k if x0 ≤ x < x1
0 if x < x0 (nonconductors)
δ010
2(x−x0) if x < x0 (conductors)
As a starting point, I did not consider secondary effects, higher order terms, nuclear
effects or correction terms. Highly relativistic effects were not taken into account
for βγ > 500.
A.1 Limits on Accuracy
As stated by the particle data group, there is an inherent limit on accuracy of a
few % for intermediate Z materials. In the Bethe Bloch model there is no range
or energy straggling; it is a very limited approach. A simple βγ calculator can be
written to show how the βγ value changes with energy, since it only depends on
energy relativistically in the following way:
βγ =
√
2
K
mc2
+
K2
m2c4
(A.2)
Where K is the kinetic energy. At the lower limit of validity of βγ > 0.05 the
solution is K = 1.172MeV or K = −1877MeV (not physical). At the upper limit
of validity of βγ < 500 the solution is K = 468GeV or K = −470GeV (not
physical), well beyond the highest energies required for proton therapy. Ergo for
any practical purposes, we can say for K > 1.172MeV the Bethe Bloch model is
valid.
Here it is assumed that all the deposited energy is absorbed locally from
Coulomb effects in a CSDA; this is not truly the case. Approximations on the
constants will have small effects. Equally, while the approximations on the Z/A
value which is built in to the program will have small effects it is important to
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Figure A.1: Uncertainty in mean ionization potential I will cause shifts in range
(range uncertainties) for the Bragg peaks (Andreo, P., 2009).
know these values accurately or else wildly inaccurate values will be outputted.
There are no nuclear, secondary effects, or higher order terms (δ, ) being taken
into account in this model.
The mean excitation potential I stands as the single most important variable
to determine accurately in this model. This variable changes depending on the
absorber Z value. Any analytic fit to this curve would rely on heavy approximation
which may swing the outputs of the model to give results which are wrong; despite
this some people do take I/Z = 10eV.
The stopping powers of protons in water are important quantities in proton
therapy since they determine absorbed doses to water. These stopping powers
were provided by the ICRU in Report 49 using the stopping power formula with
a mean excitation energy (I-value) of water of 75 ± 3 eV. After the ICRU work
was completed, new values of 80 ± 2, 81.8, and 77 eV were reported. The dif-
ference in the I-values between 75 and 80 eV results in 0.8% - 1.2% differences
in the stopping power in the energy range of 10 - 250 MeV, which implies the
same impact on absorbed doses. It is therefore important to verify the I-value.
The ranges were determined from the depth dose curves of mono-energetic beams
(Bragg curve) measured in a water phantom. The proton energies at the syn-
chrotron were determined with good accuracy. The I-value was determined to be
78.4 ± 1.0 eV, so that the ranges calculated from the stopping power formula for
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the proton energies at the synchrotron agreed with the measured ranges. The
uncertainty came from the ambiguity in the range determination from the Bragg
curves, the water-equivalent thicknesses of the devices in the beam line, and the
displacement error of the detector in the water phantom. In my opinion the pre-
vious section contains everything that can be done using the Bethe Bloch model
for proton therapy modelling usefully.
A.1.1 Numerical Method
The Bethe Bloch equation is too complicated to solve analytically, so therefore in
solving this I used a numerical approach. One possibility is to use an iterative
form of solution. Since the right hand side of Eq.A.1 has no x dependence and
only energy, for small x one can compute:
dE
dx
dx = dE (A.3)
→ dE(x+ dx) = E(x)− dE
dx
dx (A.4)
The integral first needs to be solved in order to obtain the x dependence. Once
this is implemented, this can be used to create programs; an example of this is to
sum the dE contributions to produce an energy (dose) calculator between limits
in x → x + dx. However for the integral to find the range the integral shown in
Eq.A.5 can be readily evaluated.
x− x0 =
∫ E
E0
(
dE
dx
)−1
dE (A.5)
This integral works because of the energy dependence in Eq.A.1, meaning that
we can readily step in kinetic energy to perform the integral and implement a
trapezoid method to perform this integral numerically.
dA =
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dE
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)2
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It may be interesting to consider the comparison between the Bethe Bloch
equation and the CSDA model in terms of range predictions. In order to visualise
this comparison I have plotted in figure A.2 the range against energy for both
calculation types. By inspection, the plots look similar and by eye the difference
can only be seen at energies greater than 200MeV. The well-known relativistic
form of kinetic energy is given by:
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Figure A.2: Agreement between my program which solves the Bethe Bloch equa-
tion and performs the integral using a trapezoid approximation, and the CSDA
using values from ICRU 49.
K = (γ − 1)mc2 → γ = 1 + K
mc2
(A.7)
γ =
1√
1− β2 → β =
√
1− 1
γ2
(A.8)
From Eqs.(A.7,A.8):
β =
√
1− 1(
1 + K
mc2
) ⇒ βγ = (1 + K
mc2
)√
1− 1(
1 + K
mc2
) (A.9)
Eq.(A.9) simplifies to:
βγ =
√
2
K
mc2
+
K2
m2c4
(A.10)
Appendix B
Omitted Theory from the Main
Thesis for the Bortfeld Model
Referring back to the thesis for the symbolic definitions (chapter 2).
Dˆ1(z) = Dˆ1(z)(z¯(E0,∆E)) (B.1)
In the previous case where we assumed no depth straggling we found: Dˆ1(z) =
a1(R0 − z)1/p−1. Now we must consider that the z term here is in fact a z¯ term.
⇒ Dˆ1(z¯) = a1(R0 − z¯)1/p−1 (B.2)
We want Dˆ1 for the actual dose delivered at z including the Gaussian distribution
of z, not just the mean. The dose D1 at the actual depth z is given by the
convolution of Dˆ1(z¯) with the Gaussian distribution of z¯ (see Figure B.1).
Dˆ1(z) ∼ Dˆ1(z¯)⊗ e
−(z−z¯)2/2σz(z¯)2√
2piσz(z¯)2
(B.3)
So from the convolution theorem:
⇒ D1(z) =
〈
Dˆ1(z)
〉
=
∫ R0
z¯=0
Dˆ1(z¯)
e−(z−z¯)
2/2σz(z¯)2√
2piσz(z¯)2
dz¯ (B.4)
Convolving Dˆ2(z) in a similar way, in the Bortfeld assumption that it can be done
in the same way as Dˆ1(z) (Bortfeld states these protons which undergo nuclear
effects have a smaller contribution to the overall dose and are less critical).
In the previous case where we assumed no depth straggling we found: Dˆ2(z) =
a2(R0 − z)1/p. Now we must consider that the z term here is in fact a z¯ term.
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Figure B.1: How convolution on the idealised asymptotic Bragg curves with a
Gaussian for the range straggling produces the desired realistic Bragg peak.
⇒ Dˆ2(z¯) = a2(R0 − z¯)1/p (B.5)
We want Dˆ1 for the actual dose delivered at z including the Gaussian distribution
of z, not just the mean.
Dˆ2(z) ∼ Dˆ2(z¯)⊗ e
−(z−z¯)2/2σz(z¯)2√
2piσz(z¯)2
(B.6)
From the convolution theorem:
⇒ D2(z) =
〈
Dˆ2(z)
〉
=
∫ R0
z¯=0
Dˆ2(z¯)
e−(z−z¯)
2/2σz(z¯)2√
2piσz(z¯)2
dz¯ (B.7)
σz(z¯) is range dependent, as one would intuitively expect; a mininum of σz(z¯ =
0) = 0 and a maximum of σ = σz(z¯ = R0). However, when considering the
integrals above to solve for D1(z) and D2(z) Bortfeld suggests the integrals can be
approximated with very high accuracy by assuming σz(z¯) = σ. An explanation of
this is as follows. At low depths where σz(z¯) << σ, Dˆ1 and Dˆ2 are flat depth-dose
distributions so the effect of convolving with a Gaussian is negligible. Since we
have this same value of σz(z¯) = σ for both Dˆ1(z) and Dˆ2(z), from Eqs.(2.16, B.4,
B.7):
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〈
Dˆ1(z)
〉
+
〈
Dˆ2(z)
〉
=
∫ R0
z¯=0
(Dˆ1(z) + Dˆ2(z))dz¯ =
〈
Dˆ(z)
〉
= D(z) = D1(z) +D2(z) (B.8)
∴ D(z) =
〈
Dˆ(z)
〉
=
∫ R0
z¯=0
Dˆ(z¯)
e−(z−z¯)
2/2σ2
√
2piσ2
dz¯ (B.9)
Eq.(B.9) is the integral to be solved, using our result for Dˆ(z¯) contained in
Eq.(2.16). From Eqs.(B.9, 2.16):
D(z) =
〈
Dˆ(z)
〉
=
1√
2piσ
∫ R0
z¯=0
Dˆ(z¯)e−(z−z¯)
2/2σ2dz¯ =
〈
a1(R0 − z)1/p−1 + a2(R0 − z)1/p
〉
=
1√
2piσ
∫ R0
z¯=0
[
a1(R0 − z)1/p−1 + a2(R0 − z)1/p
]
e−(z−z¯)
2/2σ2dz¯ (B.10)
=
1√
2piσ
∫ R0
z¯=0
a1(R0 − z)1/p−1e−
(z−z¯)2
2σ2 dz¯ +
1√
2piσ
∫ R0
z¯=0
a2(R0 − z)1/pe−
(z−z¯)2
2σ2 dz¯
(B.11)
So the integral we are looking to solve is of the form:
F (z,R0) =
1√
2piσ
∫ z¯=R0
z¯=−∞
(R0 − z¯)ν−1e−
(z−z¯)2
2σ2 dz¯ (B.12)
Making the substitution, let h = R0 − z¯, y = R0 − z. Therefore dhdz¯ = −1.
h− y = z − z¯
(h− y)2 = (z − z¯)2 = h2 + y2 − 2hy
Therefore Eq.(9.12) becomes:
F (z,R0) = − 1
σ
√
2pi
∫ z¯=R0
z¯=−∞
hν−1e−
(h2+y2−2hy)
2σ2 dh = − 1
σ
√
2pi
∫ z¯=R0
z¯=−∞
hν−1e−
y2
2σ2 e−
h2−2hy
2σ2 dh
For the limits when z¯ = −∞, h = +∞. When z¯ = R0, h = 0.
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∴ F (z,R0) = − e
−y2
2σ2√
2piσ
∫ h=0
h=∞
hν−1e−
h2−2hy
2σ2 dh =
e
−y2
2σ2√
2piσ
∫ h=∞
h=0
hν−1e−
h2−2hy
2σ2 dh
(B.13)
This integral can be solved in closed form, using the reference provided at this
point in Bortfeld’s paper. The result is:
F =
e−
y2
2σ2√
2piσ
(
1
σ2
)−ν
Γ(ν)e
y2
4σ2D(p)−ν
(
−y
σ
)
=
1√
2piσ
e
y2
4σ2 σνΓ(ν)D(p)−ν
(
−y
σ
)
(B.14)
Simply...
1√
2piσ
∫ z¯=R0
z¯=−∞
(R0 − z¯)ν−1e−
(z−z¯)2
2σ2 dz¯ =
1√
2piσ
e
y2
4σ2 σνΓ(ν)D(p)−ν
(
−y
σ
)
(B.15)
Where Γ(x) is the gamma function and D(p)a(x) is the parabolic cylinder function.
The gamma function is just a constant for constant p. There are calculators online
which can compute the value of the gamma function for non-integer forms. We
now have the solutions that we needed for Eq.(B.11) for our equation for D(z);
the depth dose formula including range straggling. So inputting this result, from
Eqs.(B.11, B.15) and using our previously defined values for a1 and a2 in Eq.(2.16):
a1 = Φ0
1
ρ(1 + βR0)pα1/p
(B.16)
a2 = Φ0
β(1 + pγ)
ρ(1 + βR0)pα1/p
(B.17)
I1 = a1
1√
2piσ
e
y2
4σσ
1
pΓ
(
1
p
)
D(p)− 1
p
(
−y
σ
)
(B.18)
I2 = a2
1√
2piσ
e
y2
4σσ
1
p
+1Γ
(
1
p
+ 1
)
D(p)− 1
p
−1
(
−y
σ
)
(B.19)
∴ D(z) = a1 1√2piσe
(R0−z)2
4σ σ
1
pΓ
(
1
p
)
D(p)− 1
p
(− y
σ
)
+a2
1√
2piσ
e
(R0−z)2
4σ σ
1
p
+1Γ
(
1
p
+ 1
)
D(p)− 1
p
−1
(
−y
σ
)
(B.20)
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Let ζ = R0−z
σ
. So the first term in Eq.(B.20) becomes:
Φ0e
ζ2
4 σ
1
pΓ
(
1
p
) [
1
σ
D(p)− 1
p
(−ζ)
]
√
2piρ(1 + βR0)pα
1
p
(B.21)
The second term in Eq.(B.20) becomes:
Φ0e
ζ2
4 σ
1
pΓ
(
1
p
+ 1
) [
β(1 + pγ)D(p)− 1
p
−1(−ζ)
]
√
2piρ(1 + βR0)pα
1
p
(B.22)
Using the result that:
Γ
(
1
p
+ 1
)
= Γ
(
1
p
)
1
p
(B.23)
B.1 Omitted Gaussian and Bortfeld Tail for The-
ory Chapter
B.1.1 Inclusion of the Polyenergetic Considerations
So far it has been assumed that the proton beam is initially monoenergetic. It
is stated in the Bortfeld 1997 paper that assumption unfortunately, does not cor-
respond with reality. Proton beams have an initial spectral energy distribution,
which depends on the individual characteristics of the accelerator, the beam guide,
and the collimation system (Bortfeld, 1997). The energy spectrum ΦE(E)∆E
which is the number of protons per cm2 with energies between E and E + ∆E
can be quite different from the ideal δ shape. A way to consider the energy spec-
trum is to perform a weighted superposition of mono-energetic Bragg curves with
weights ΦE. In general, there is no analytical solution to this problem, so that
numerical methods have to be used. It is stated in the paper that Bortfeld uses
an approximation, which allows for an analytical solution.
Bortfeld introduces the typical energy spectra consisting of two parts: a peak,
which can be approximated by a Gaussian energy spectrum around E = E0, and
a relatively small “tail extending toward low energies. Let σE,0 be the standard
deviation of the Gaussian. Since σE,0 is generally small σE,0 << E, the simple
range-energy relationship can be linearized around E = E0. Hence, the Gaussian
energy spectrum translates into a Gaussian range spectrum, whose variance adds
to the σ2mono of the monoenergetic beam:
σ2 = σ2mono + σ
2
E,0
(
dR0
dE0
)2
= σ2mono + σ
2
E,0α
2p2E2p−20 (B.24)
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Consequently, the Gaussian energy spectrum can be considered simply by in-
creasing the σ. Here we account for a Gaussian range spectrum. However, since
the depth-dose depends primarily on the distance between range and depth, this
conceptual difference has no practical significance.
The consideration of the tail of the energy spectrum is more difficult because
it may depend on many different factors, and its exact shape is not generally
known. We can utilize the fact that the total fluence corresponding with the tail
is only a relatively small fraction,  of the fluence Φ0 in the peak. For this reason,
coarse models to approximate the spectrum of the tail can be used. A very simple
model that agrees at least with the expectation that ΦE(E) should be negligible
at E = 0 and have a positive slope for small E is a linear ramp: ΦE(E) ∝ E for
0 <= E <= E0. Normalising the integral of ΦE(E) to Φ0 gives the result:
ΦE(E) = Φ0
2E
E20
(B.25)
To avoid a discontinuity of the energy spectrum at E = E0, the sharp edge of
the ramp should be “smeared”. This will be done by means of the incorporation
of straggling. It should be noted that the average tail-to-peak ratio of the energy
spectrum is
√
2piσE,0/E0, which is in the order of only 2-3% of .
To calculate the depth dose distribution resulting from the linear energy spec-
trum, it is necessary to translate ΦE(E) into a range spectrum ΦR(R), where
ΦR(R)∆R is the fluence of protons with ranges between R and R + ∆R. This
is accomplished by means of the relation ΦR(R) = ΦE(E(R))dE/dR. Using the
range-energy relationship gives:
ΦE(R) = Φ0
2R2/p−1
E20pα
2/p
(B.26)
This means that the range spectrum resuslting from the linear energy spectrum is
approximately constant (2/p− 1 << 1). In fact, with the approximation p ≈ 2 we
obtain:
ΦR(R) ≈ constant = Φ0 1
R0
(B.27)
The range spectrum must be convolved with the individual depth dose distribution
as a function of the range to obtain the total depth dose distribution Dtail, resulting
from the tail of the energy spectrum. Bortfeld makes simplifications which can be
justified due to the relatively small value of . First we will go back to the case
where range straggling was ignored. Here the dose delivered by protons which have
nuclear interactions will be disregarded, ie. it will be assumed that Dˆ(z) = ˆD1(z).
Now we can write Dˆ1 as a function of z and R instead of R0 and perform the
convolution as follows:
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Dˆtail(z) ≈ 1
Φ0
∫ R0
z
ΦR(R)Dˆ1(z,R)dR (B.28)
≈ Φ0
R0ρpα1/p(1 + βR0)
∫ R0
z
(R− z)1/p−1dR
=
Φ0
R0ρpα1/p(1 + βR0)
(R0 − z)1/p
This expression is of the same form as the second term Dˆ2. Straggling can now be
considered in the same way as in the previous section, which results in the final
expression Dtail(z). I included the  term which takes the polyenergetic beam into
account directly in the simulation model that I have written. Our old expression
which is written up becomes:
Dˆ(z) =
Φ0
1 + βR0
[
1
ρpα1/p
(R0 − z)1/p−1 +
(
β
ρpα1/p
+
βγ
ρα1/p
+

R0ρα1/p
)
(R0 − z)1/p
]
(B.29)
The new term is from the +Dˆtail(z). Also the other old expression becomes:
D(z) =
Φ0e
− ζ2
4 σ
1
pΓ
(
1
p
)
√
2piρ(1 + βR0)pα
1
p
[
1
σ
D(p)− 1
p
(−ζ) +
(
β
p
+ γβ +

R0
)
D(p)− 1
p
−1(−ζ)
]
(B.30)
The new term is from the +Dtail(z).
Dˆtail(z) =
Φ0
R0ρα1/p(1 + βR0)
(R0 − z)1/p (B.31)
Straggling considered in the same way → Dtail(z).
B.2 Special Functions in the Bortfeld Formula
Special Functions in Eq.(B.30)
Mathematica was used to calculate the values required for the parabolic cylinder
function in D, since it outputs a nice plot of the Dv(x) function against x for a
fixed v, and this is what we require for the calculation. So by stepping in dz and
using Mathematica to compute D(p)ν(x) = D(p)− 1
p
(−ζ) = D(p)− 1
p
(−R0−z
σ
)
and
D(p)ν(x) = D(p)− 1
p
−1(−ζ) = D(p)− 1
p
−1
(−R0−z
σ
)
we can generate the outputs for
the required functions.
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Parabolic Cylinder Function
The parabolic cylinder functions are a class of functions sometimes called Weber
functions. There are a number of slightly different definitions in use by various
authors. Whittaker and Watson (1990, p. 347) define the parabolic cylinder
functions Dν(z) as solutions to the Weber differential equation:
y′′(z) +
(
v +
1
2
− 1
4
z2
)
y(z) = 0 (B.32)
For a more complete mathematical explanation of what these functions are and
how they behave, see for example: An Atlas of Functions: With Equator, the Atlas
Function Calculator By Keith B. Oldham, Jan C. Myland.
Gamma function
The Gamma function for Re[z] > 0 is given by (Euler’s integral form):
Γ(z) =
∫ ∞
0
tz−1e−tdt (B.33)
Or by Euler’s formula for (z 6= 0,−1,−2, ...):
Γ(z) = lim
n→∞
(
n!nz
z(z + 1)...(z + n)
)
(B.34)
Since the gamma function Γ(p) is constant for constant p, there is no real need to
implement a calculator by hand. However, for the reader’s interest, an implemen-
tation which could be used follows. In my computation of the Gamma function I
am using the Lanczos approximation. In mathematics, the Lanczos approximation
is a method for computing the Gamma function numerically, published by Cor-
nelius Lanczos in 1964. It is a practical alternative to the more popular Stirling’s
approximation for calculating the Gamma function with fixed precision.
B.3 Consideration of the Energy Spectrum
So far it has been assumed that the proton beam is initially mono-energetic. As
is written in Bortfeld, 1997, that assumption unfortunately does not correspond
with reality. Real beams have an initial spectral energy distribution, which de-
pends on the individual characteristics of the accelerator, the beam guide, and the
collimation system.
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B.4 Depth Dose Distribution Without Range Strag-
gling
Using our previous results:
−∂Φ(z)
∂z
= Φ0
β
1 + βR0
(B.35)
Φ(z) = Φ0
1 + β(R0 − z)
1 + βR0
(B.36)
E(z) =
1
α1/p
(R0 − z)1/p (B.37)
−∂E(z)
∂z
=
1
pα1/p
(R0 − z)1/p−1 (B.38)
Dˆ(z) = −1
ρ
(
Φ(z)
∂E(z)
∂z
+ γ
∂Φ(z)
∂z
E(z)
)
(B.39)
Inputting these results:
Dˆ(z) =
1
ρ
(
Φ0
1 + β(R0 − z)
1 + βR0
1
pα1/p
(R0 − z)1/p−1 + γΦ0 β
1 + βR0
1
α1/p
(R0 − z)1/p
)
=
Φ0(1 + β(R0 − z))(R0 − z)1/p−1 + pγΦ0β(R0 − z)1/p
ρ(1 + βR0)pα1/p
Dˆ(z) = Φ0
(R0 − z)1/p−1 + β (1 + pγ) (R0 − z)1/p
ρ (1 + βR0) pα1/p
(B.40)
B.5 Determination of the Range Straggling Width
From the formula given in H.Bethe and J.Askhin’s “Passage of radiations through
matter”, (Bortfeld, 1997), the mean square spread in the range σ2, for a given
mean square spread in the residual energy σE, for a given depth z is given by:
σ2 =
∫ R0
0
d
dz
(σ2E)
(
dE
dz
)−2
dz (B.41)
For energies above about 10 MeV, the term d
dz
(σ2E) can be approximated using
Bohr’s classical formula (Bortfeld, 1997):
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d
dz
(σ2E) ≈
1
4pi
e4NZ = α′ (B.42)
Here e is the electron charge, NZ is the electron density of the stopping matter.
For water we obtain: α′ ≈0.0087MeV2/cm. Using our previous result for stopping
power in Eq.(2.5), along with Eqs.(B.41,B.42):
σ2 = α′
∫ R0
z=0
(
1
pα
1
p
(R0 − z)
1
p
−1
)−2
dz (B.43)
= α′p2α
2
p
∫ R0
z=0
(R0 − z)2−
2
pdz
Solving this integral by substitution, we find:
σ2 = α′p2α
2
p
R
3− 2
p
0
3− 2
p
=
α′p3α
2
p
3p− 2 R
3− 2
p
0 (B.44)
Appendix C
NIST Algorithm
The NIST algorithm for computing Dν(x) (National Institute of Standards and
Technology) is quite adequate for within the Bortfeld Bragg peak limits (the re-
quired formulation before this is a hatted formulation of Dˆ(z) which is easily
computable). It is given by the following, the parabolic cylinder functions in D
are defined as:
Dν(x) = cos
(piν
2
)
w1(x) + sin
(piν
2
)
w2(x) (C.1)
Where:
w1(x) =
1√
pi
Γ(0.5 + 0.5ν)
2−ν/2
y1(x) (C.2)
w2(x) =
1√
pi
Γ(1 + 0.5ν)
2−ν/2−0.5
y2(x) (C.3)
y1(x) =
∞∑
m=0
a2m
x2m
(2m)!
(C.4)
y2(x) =
∞∑
m=0
a2m+1
x2m+1
(2m+ 1)!
(C.5)
The a coefficients are determined from the following recursive formula:
a0 = a1 = 1 (C.6)
a2 = a3 = a = −ν − 0.5 (C.7)
For n ≥ 4:
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an = a× an−2 + 1
4
(n− 2)(n− 3)an−4 (C.8)
Appendix D
Benchmark of the Geometrical
Lung Model
From clinical/textbook data there are two points to extract: from the paper “The
number of alveoli in the human lung” (Ochs, M. et al, 2004):
1. The dimension of an alveolus is 0.208mm side length (from the paper which
gives 170 per cubic mm)
2. The average total number in both lungs is 480 million (from the paper)
There is also a 2nd different relevant (and important) paper under a very similar
name (no “The”): “Number of alveoli in human lung” (Angus et al., 1972). In this
paper the authors claim evidence has suggested that the total number of alveoli
in the human lung is fairly constantly 300×106 although widely varying numbers
have been reported in the older literature. Taking the result from the more recent
paper: this is very clearly stated in the paper in the results section where they
state the number for both lungs can be obtained by multiplying the number for 1
(240M) lung by 2 (480M).
Using this information we can mathematically calculate assuming a spacing S
the correct average dimensions to reflect this assuming a homogeneous distribution
in 3D. 170 alveoli per mm3 regularly spaced and 480M for both lungs total - what
are resulting dimensions with a spacing of S between the lungs? Looking at the
paper: Linear dimensions and volumes of human lungs obtained by CT images by
Kramer, G.,H. et al., 2010, there is an image in this paper which shows a boxplot
which is discussed in section 2 of this report. The bio-textbook: Seeley, Stephens
and Tate, Essentials of anatomy and physiology states that (for both lungs) the
total lung capacity is the sum of the inspiratory and expiratory reserves and the
tidal and residual volumes are 5800cm3 (average result).
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From the paper by Kramer, G.,H. et al, 2012, the peak to peak height was
found to be 21.0±2.1cm, width 12.3±0.1cm. In the double cuboid model this
implies an average volume for both lungs of 2×21.0× 12.32cm3 ≈ 3.18× 106mm3.
Therefore taking the result 170/mm3 we find 540M alveoli total which is of the
same order as the value in papers, so appears to show a good benchmark at 1st
order.
Appendix E
Validation
E.1 Validation Description
Simulation models are increasingly being used to solve problems and to aid in
decision-making. The developers and users of these models, the decision makers
using information obtained from the results of these models, and the individuals
affected by decisions based on such models are all rightly concerned with whether a
model and its results are “correct”. This concern is addressed through verification
and validation of the simulation model.
To match the simulation model to a case where we should be able to find out
the outcome at a known Vx% value and see how well the predictions of the EUD
model match to the data sets used. Since there is a full organ irradiation in the
simple case of 1D it is therefore a benchmark of the models used which are modern
day. Once this is done (at large volumes) then we know that the lung/proton/X-
ray model I have made has predictive power and can be meaningfully applied at
lower volumes for the investigation of this work. The two metrics which are to
be compared are the V25 “favoured” in the literature and the mean lung dose to
validation.
E.2 1D Comparison Validation Results Between
QUANTEC and EUD
Trials to see agreements between EUD and QUANTEC in a uniform dose irra-
diation. Verification: finding agreement between EUD and QUANTEC in the
simplest cases then finally look at example of uniform case. EUD model (symbolic
definitions presented earlier in this thesis) in the case of lung tissue a = 1:
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EUD = ΣiviDi (E.1)
NTCP =
1
1 +
(
TD50
EUD
)4γ50 (E.2)
The old Emami parameters are: TD50 = 24.5 and γ50 = 2. MLD (Mean Lung
Dose) logisitic fit:
NTCP =
eb0+b1·MLD
1 + eb0+b1·MLD
(E.3)
With the Marks parameters as: b0 = −3.87, b1 = 0.126, TD50 = 30.8,
γ50 = 0.97. Considering an array of 10 voxels in one dimension, for the ini-
tial arrangement I ran 25Gy in each voxel: since there are 10 voxels the EUD
value turns out as 25 (a dimensionless quantity). The corresponding NTCP value
which is produced when Eq. E.2 is used with the old Emami parameter values
for TD50=24.5 and γ50=2 is: NTCP=0.54. When this same equation is used but
with the Marks values for the parameters of TD50=30.8 and γ50 = 0.97 the result-
ing NTCP is: NTCP=0.308. Now computing the same thing but with the MLD
logisitc fit using Eq. E.3 and the values of the parameters listed above produces
a value of: NTCP=0.308, which is a strong agreement between the two differing
methods.
For the next trial, allocating 40Gy into each voxel. Since there are 10 vox-
els (and modelling the lung as a=1) here this produces a value of EUD=40.
Modelling with the new values of the parameters from the Marks study. It is
found that: NTCP(EUD)=0.7338. And for the MLD logistic fit, it is found:
NTCP(MLD)=0.763, this is a good agreement. For the next trial, allocating 50Gy
into each voxel. EUD=50. New values which are found (using the new parameters)
when the above equations are used: NTCP(EUD)=0.919. NTCP(MLD)=0.868.
Trialling 15 Gy into each voxel EUD=15. New values which are found (using
the new parameters) when the above equations are used: NTCP(EUD)=0.121.
NTCP(MLD)=0.058. Trialling 20 Gy into each voxel EUD=20. New values
which are found (using the new parameters) when the above equations are used:
NTCP(EUD)=0.206. NTCP(MLD)=0.156.
When comparing the Vx value predictions to the EUD there are limitations of
the methods used and this is referenced in the literature, and there will be cases
where it is not possible for all the Vx values to find an agreement (a popular
result from the literature is that for the lung the most favoured value to use is
the V25 value for lung). I conclude in this section that there are certain cases
where it is appropriate following the examinations I have just done to study V20
for uniformity and V13 for 1/3 of total lung irradiation.
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To begin with, studying the V5 value. Selecting V5=30% with once again
the 10 voxels arrangement. The probability from the dataset associated with
V5=30% is 4.14%. With the old Emami values the EUD which corresponds to this
probability is 16.5. With the Marks parameter values the EUD which corresponds
to this probability is 13.7. Therefore the V5=30% demands a construction where
30% of the 10 voxels contain dose values ≥ 5Gy and the rest of the voxels contain
< 5Gy. So therefore which construction is required to achieve this can be found
and how uniform it is can be determined.
Let us assume a mean lung dose value of 25Gy, and work with the V25 pa-
rameter here. An approximately uniform structure of dose can be achieved by
assuming an alternating dose assignment of 24Gy, 26Gy, 24,... Here the results for
the calculated EUD vs the data based NTCP values give probabilities of 54.0% for
the calculated EUD and 82.7% for the data based NTCP (however it should be
noted here this value is outside the data range). Staying with the V25 parameter,
in the next case we assign a dose deposition corresponding to V25=30%: 24Gy
in 7 of the 10 voxels and 26Gy in 3 of the voxels. Using the same formulas and
methodology described above, this results in a data based NTCP of 37.85% and
from the EUD model a NTCP result of 50.8%. In the V25=20% case, this assumes
a dose deposition of 26Gy in 2 of the 10 voxels and 24Gy in 8 of the 10 voxels,
again achieving approximately a uniformity of dose deposition. The NTCP arising
from the EUD model in this case is: 49.18% and the NTCP arising from the data
prediction is 15.45%.
To conclude here I found in certain cases where it is apparent from this study
comparing the predicted values from the Vx data and the EUD model that in
the majority of cases there will be poor agreement however in certain cases there
will be good agreement, and the assessment of this, as well as the implications for
the conclusions of this study is as follows: in its simplest form this provides an
inherent limitation on the results we can achieve. Selected cases have been shown.
Appendix F
Linear Energy Transfer Depth
Model and Innovations Made
F.1 Introduction and Use of the Existing Method-
ology
When protons travel through a medium (water) they exhibit a characteristic Bragg
peak; this fact is used in proton radiotherapy, to spare normal healthy tissue
from dose while delivering dose to the tumour region (Wilson, R.R., 1946). This
technical note requires some familiarity with two papers in particular, Bortfeld’s
paper on single Bragg peaks (Bortfeld, T., 1997), and Wilkins&Oelfke’s paper on
analytical LET calculations (Wilkens, JJ and Oelfke, U, 2003).
Wilkens and Oelfke state that all LET definitions are based on the stopping
power. The total linear stopping power S for a given material is the sum of the
linear collision stopping power Scol and the linear radiative stopping power Srad.
As the latter can be neglected for therapeutic protons, (ICRU Report 49, 1993)
we get (where dE is the energy lost by a proton in traversing a distance dl (ICRU
Report 60, 1998)):
S = Scol =
(
dE
dl
)
col
(F.1)
The term LET is also employed to describe a mean value of the stopping
power. This mean can be calculated either along the track of a single particle
(ICRU Report 16, 1970), (Hall, E.J., Radiobiology for the Radiologist, 5th ed.,
2000) or by averaging the stopping powers of all particles at a certain point in
a radiation field (Berger, M.J., 1993). The latter approach will be used in this
appendix: we define LET as a local mean of the stopping power S. We are using
Bortfeld’s Bragg peaks in this model (Bortfeld, T., 1997). The expectations include
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the fluence terms integrated over all protons with residual ranges r. For the dose
averaged LET, we are indeed summing over all beams. z is the direction of the
beam in real units (cm).
Ld (~x) =
Σnj=1 〈S2〉z
Σnj=1 〈S〉z
(F.2)
For a single beam, simply:
Ld (~x) =
〈S2〉z
〈S〉z
(F.3)
ζ =
z −R0
σ
(F.4)
ξ =
z −R0 −R
σ
(F.5)
D˜1+1/p(ξ, ζ) = e
−ξ2/4D(p)−1−1/p(ξ)− e−ζ2/4D(p)−1−1/p(ζ) (F.6)
D˜ 2
p
(ξ, ζ) = e−ξ
2/4D(p)−2/p(ξ)− e−ζ2/4D−2/p(ζ) (F.7)
The two dimensional part of D˜1+ 1
p
(ξ, ζ) and D˜ 2
p
(ξ, ζ) are from output stepping in
z for a given R0 value. ζ is unregularised and ξ is regularised.
〈
S2
〉
z
=
Φ0√
2piσRα2/pp(2− p)
[
σ
2
pΓ
(
2
p
)
D˜ 2
p
(ξ, ζ)− 2
(
1
2
R
) 2
p
e−
(ξ+ζ)2
8
]
(F.8)
〈S〉z =
Φ0√
2piσRα1/p
(
σ1+1/pΓ(1 + 1/p)D˜1+1/p(ξ, ζ)−R
(
1
2
R
)1/p
e−
(ζ+ξ)2
8
)
(F.9)
Σnj=1 〈S〉z = 〈S〉R01z + 〈S〉R02z + ...+ 〈S〉R0nz (F.10)
Similarly the counterpart,
Σnj=1
〈
S2
〉
z
=
〈
S2
〉R01
z
+
〈
S2
〉R02
z
+ ...+
〈
S2
〉R0n
z
(F.11)
Where ν1 = −1− 1/p, ν2 = −2/p, x1 = ζ, x2 = ξ.
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The NIST algorithm for computing Dν(x) (Appendix C) is quite adequate for
within the Bortfeld Bragg peak limits (the required formulation before this is a
hatted formulation of Dˆ(z)). It is given by the following. The parabolic cylinder
functions in D are defined as:
Dν(x) = cos
(piν
2
)
w1(x) + sin
(piν
2
)
w2(x) (F.12)
Where:
w1(x) =
1√
pi
Γ(0.5 + 0.5ν)
2−ν/2
y1(x) (F.13)
w2(x) =
1√
pi
Γ(1 + 0.5ν)
2−ν/2−0.5
y2(x) (F.14)
y1(x) =
∞∑
m=0
a2m
x2m
(2m)!
(F.15)
y2(x) =
∞∑
m=0
a2m+1
x2m+1
(2m+ 1)!
(F.16)
The a coefficients are determined from the following recursive formula:
a0 = a1 = 1 (F.17)
a2 = a3 = a = −ν − 0.5 (F.18)
For n ≥ 4:
an = a× an−2 + 1
4
(n− 2)(n− 3)an−4 (F.19)
As stated earlier, for a real evaluation from z = 0 where z is the beam direction
in real units of distance, this algorithm breaks down and is of no use. There-
fore an alternative which can be fully automated and used analytically must be
found. This appendix is concerned with work to address this issue. The method of
interpolating the function space is original and is the focus of this technical note.
The units on the outputs are as generated by the LET model. The ν1 and ν2
cases exist respectively because they feature in both expectations respectively. The
value of the resulting D˜ function is given by the difference between the regularized
term and the non-regularized term as in Eqs.(F.6, F.7). Each of these is a separate
function for which the interpolation method is used (4 parts in total).
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F.2 Method: Linear Interpolation of the Func-
tion Space
The non interpolated values of R0 which make up the overall set of Bragg peaks
become interpolated by a step size of ∆. For example with ∆ = 0.01cm, a Bragg
peak with R0 = 5.00499cm becomes R0 = 5cm from the interpolation. Similarly, a
Bragg peak with R0 = 5.005cm becomes a Bragg peak of R0 = 5.01cm. Then the
relevant data for the f(e)f(D) values for the calculation of D˜ for ν1 and ν2 can be
read from the readfiles which were generated using this particular ∆. The accuracy
is defined as the value of D˜ produced by the interpolation method compared to
the true value of D˜. The question is therefore how accurate is this method (with
adjustable parameters). Mathematica was used to generate the read files. A given
interpolation step size was chosen in cm ∆. Limitation at the upper end (0.1% of
the max dose (Wilkens and Oelfke, 2003) of most distal Bragg peak for calculating
the LET up to).
F.2.1 Quantitative Evaluation of the Acccuracy and Va-
lidity of the Mean Value Approximation for Overall
Accuracy Evaluation for the Method
Assertion for the Mean Value Approximation. Where θ is ζ or ξ, and ν is ν1 or ν2:
e−
θ2
4 D(p)ν(θ)
∣∣∣∣
θ=θ(R0+
∆
2
)
≈ 1
2
(
e−
θ2
4 D(p)ν(θ)
∣∣∣∣
θ=θ(R0)
+ e−
θ2
4 D(p)ν(θ)
∣∣∣∣
θ=θ(R0+∆)
)
(F.20)
This is introduced to remove the requirement for the readfiles being generated for
the intermediate values which are worst case scenarios for the interpolation. For
ν1 or ν2 the D˜ is generated across all z across all R0 for a given ∆. These can be
compared to the D˜ from the intermediate values (always rounding up at exactly
the halfway point), allowing us to discern the accuracy of the method.
Therefore firstly it is important to determine the accuracy of this approximation
compared to the true intermediate function shapes, for a given ν1 or ν2, e
− ζ2
4 D(ζ)
and e−
ξ2
4 D(ξ) (not required in our case for higher ∆ values because we already
generated the readfiles, although not for general ∆). We are omitting a variable
step size to prove this, and always doing the test with the interpolation step size
for ∆ = 0.01cm. I have found that a superior method to simply the sum divided
by 2, is to take the RMS:
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Figure F.1: RMS percentage error for ν1 and ν2. x1 ≈ x2 so unregularised is
discerned.
e−
θ2
4 D(p)ν(θ)
∣∣∣∣
θ=θ(R0+
∆
2
)
≈
√√√√1
2
(
e−
θ2
4 D(p)ν(θ)
∣∣∣∣2
θ=θ(R0)
+ e−
θ2
4 D(p)ν(θ)
∣∣∣∣2
θ=θ(R0+∆)
)
(F.21)
For a given ∆ = 0.01cm we have checked the accuracy for 5cm, 7cm, 9cm,
..., 25cm. For ν1 and ν2. There is no need to check for both ζ and ξ, here it is
just done for ζ because the functions are approximately the same (while distinctly
different and produce the overall result).
F.2.2 Acccuracy Results of the Method
Ideally how we would like to plot the results is as follows (for the mean value
approximation valid as tested with a fixed ∆ = 0.01cm). The accuracy output is
the 4th dimension. The 3 axes would be the overall interpolation step size ∆, the
function depth z (the max value would increase with increasing R0), and R0. The
accuracy is calculated by the true value D˜ compared to the interpolated D˜ at the
worst case R0 value (lying right in the middle between the two sides of the linear
interpolation), as a percentage.
In practice it is hard to visualise 4-dimensional plots on a 2-dimensional piece
of paper. So here we slice both into 6 plots; for ν1 and ν2 respectively, for
∆ = 0.01, 0.02, 0.04cm respectively. Here we should not talk about the percentage
error because the maximum absolute difference is what matters. For example the
percentage difference will tend towards infinity when one function only becomes
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zero (when max absolute difference, percentage difference is still small). At the
points where the values of the functions are still much greater than 0 and not much
less than the max of f(e)f(D) the absolute difference is negligible to f(e)f(D) for
the true value.
For example for a ∆ = 0.01cm, the R0 values which are chosen for the true are
5.005cm, 5.015cm, etc. The f(e)f(D) values for ν1 and ν2 respectively are calculated
by the RMS method as discussed above and depending on the accuracy of that.
For ν1 and ν2 respectively, the accuracy in absolute units is then determined by
the D˜ for the 5.01cm across all of z (from our generated readfiles) compared to
the D˜ for our 5.005cm generated from the RMS approximation.
F.2.3 Discussion
The RMS method was not used for the ∆ = 0.02cm and the ∆ = 0.04cm trials
because we already had the readfiles for that, so there is no additional error in-
curred there (we have shown that the error between the RMS and the true value
for ∆ = 0.01cm was very small and negligible, about 1 order of magnitude less
than the overall accuracy of the method).
In Wilkens paper the authors state that one does not need to compute the LET
beyond 0.1% of the max dose in z. In this appendix work, I have gone well beyond
this upper limit, such that any consideration of the max value is taken well into
account. In general the interpolation method will produce accuracies better than
this, because we are choosing the worst case scenarios of R0 values for the proton
Bragg peaks.
We find that with increasing R0, the accuracy of the method improves. Further
for a certain z value, the error is at a maximal peak. We find the error is greater
for increased ∆. As an idea of the percentage accuracy, see the figure in this
appendix which shows the absolute error overlayed to the associated D˜. Also refer
to the figure in this section which evaluates the peaks on the graphs, showing the
percentage error at the point of maximum error decreasing with increasing R0
with the percentage error for the ν1 for ∆ = 0.01cm at the most proximal R0 at
8.66%. From the inherent physics, the Bragg peaks below 5cm or so become very
sharp and therefore to create a smooth SOBP a range shifter is better used (hence
giving us our lower limit on R0).
F.2.4 Conclusions
Since we have shown that the accuracy worsens from increasing ∆ = 0.01cm to
∆ = 0.02cm to ∆ = 0.04cm at fixed z and R0, we can therefore conclude that the
accuracy improves at reduced ∆. This is much the same logic as seeing all the
galaxies moving away from each other with increasing time, therefore concluding
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Figure F.2: Absolute error of interpolation. Top row: ∆ = 0.01cm, Middle row:
∆ = 0.02cm, Bottom row: ∆ = 0.04cm. Left column: ν1, Right column: ν2.
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Figure F.3: D˜ and Absolute error of interpolation (at most proximal and highest
error R0). Top row: ∆ = 0.01cm, Middle row: ∆ = 0.02cm, Bottom row: ∆ =
0.04cm. Left column: ν1, Right column: ν2.
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Figure F.4: Percentage error at the point (in z) of maximum error. Top row:
∆ = 0.01cm, Middle row: ∆ = 0.02cm, Bottom row: ∆ = 0.04cm. Left column:
ν1, Right column: ν2.
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that at one point in the past they were all together. The accuracy for ∆ = 0.01cm
was found in this method to be 9.5% or better. Particularly higher accuracy at
higher values of R0. For the analytical LET model this method is fully automated
which is a great advantage over manually computing table values for each Bragg
peak separately of the overall SOBP. By simply reducing ∆ arbitrarily, in principle
the uncertainty becomes infintesimally small.
F.3 Method: Non-Linear Interpolation of the Func-
tion Space
The interpolation method is again as with the linear method, applied to the in-
dividual f(e)f(d)1 functions themselves. I have produced the readfiles for each
f(e)f(d) curve, for non regularised and regularised cases, for ν1 and ν2 respectively
(therefore a total of 4 curves) with a given ∆ spacing to result in a finite number
of readfiles being produced. The overall D˜ which we are seeking to obtain with
high accuracy is again given by the difference between the f(e)f(d) terms of the
non regularised and the regularised cases for a given ν1 or ν2.
In the linear interpolation method the f(e)f(d) curves were simply generated
across all possible R0 values with a given ∆ step size, allowing any naturally
occurring R0 value to be binned to the nearest f(e)f(d) value from the readfile
itself.
Here in the non linear method we are calling values of the above f(e)f(d) of
previous lines (line number shift back) to give the z result of the R0a case, and
calling values of the below f(e)f(d) of ahead lines (line number shift forwards) to
give the z result of the R0a case. Then we are doing a weighted fraction of this
depending on the ratio of R0 values to find a more accurate estimate of the result.
The R0a value is linearly interpolated to the nearest value according to the z value
spacing.
1Featured as the 4 respective terms in Eqs 13.6,13.7
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f(e)f(d)R0a
∣∣∣∣
z
= (1−fraction)f(e)f(d)R01
∣∣∣∣
z−(R0a−R01)
+(fraction)f(e)f(d)R02
∣∣∣∣
z+(R02−R0a)
(F.22)
Where,
fraction =
(R0a−R01)
(R02−R01) (F.23)
The accuracy is defined as the value of D˜ produced by the interpolation method
compared to the true value of D˜. The question is therefore how accurate is this
method (with adjustable parameters). Mathematica was used to generate the read
files. We chose a given interpolation step size in cm ∆. Limitation at the upper
end (0.1% of the max dose (Wilkens, J.J. and Oelfke, U., 2003)) of most distal
Bragg peak for calculating the LET up to.
F.3.1 Quantitative Justification of Worst-Case Scenario Ac-
curacy Evaluation at Halfway Points (R0a Values in
Steps of ∆/2)
In the linear case of interpolation it was obvious that the halfway point would
produce the worst case scenario accuracies because we are binning by the maximum
distance. However in this case it is not so intuitively obvious and a quantitative
justification of this is required and is what is presented here in this section.
To illustrate this, I generated 11 readfiles at regular intervals, between R0=5cm
and R0=5.01cm and calculated the accuracy at the point of maximum error in z
using the method described previously. It was found, as shown, that the central
point halfway between the two f(e)f(d) functions generates the largest error and
therefore one should use the central points in order to calculate the worst-case
scenario errors across all values.
F.3.2 Acccuracy Results of the Method
Ideally how one would like to plot the results is as follows. The accuracy output
is the 4th dimension. The 3 axes would be the overall interpolation step size ∆,
the function depth z (the max value would increase with increasing R0), and R0.
The accuracy is calculated by the true value D˜ compared to the interpolated D˜
at the worst case R0 value (lying right in the middle between the two sides of the
linear interpolation), as a percentage.
In practice it is hard to visualise 4-dimensional plots on a 2-dimensional piece
of paper. So here we slice both into 4 plots; for ν1 and ν2 respectively, for
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Figure F.5: Justification of the worst case scenario (largest errors of D˜) being at
halfway points ∆/2 given by the highest error being found at the central point for
this case.
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Figure F.6: Absolute error of interpolation. Top left: ∆ = 0.02cm, ν1. Top right:
∆ = 0.02cm, ν2. Bottom left: ∆ = 0.04cm, ν1. Bottom right: ∆ = 0.04cm, ν2.
∆ = 0.02, 0.04cm respectively. Here one should not talk about the percentage
error because the max absolute difference is what matters. For example infinite
percentage difference when one function only becomes zero (when max absolute
difference, percentage difference is still small). At the points where the values of
the functions are still much greater than 0 and not much less than the max of
f(e)f(D) the absolute difference is negligible to f(e)f(D) for the true values.
We have found that the accuracies achieved for ν1 and ν2 were very good.
For the ∆ = 0.02cm case, we have accuracies of the order 10−4% and for the
∆ = 0.04cm case we have accuracies of the order 10−3% at the worst case peak
scenario peak values. All other points on the plots on Figure F.6 will have better
accuracies than this.
F.3.3 Discussion
In the Wilkens and Oelfke, 2003 paper they state that one does not need to compute
the LET beyond 0.1% of the max dose in z. In this technical note we go well
beyond this upper limit, such that any consideration of the max value is taken
into account. In general the interpolation method will produce accuracies better
than this, because we are choosing the worst case scenarios of R0 values for the
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Figure F.7: D˜ and Absolute error of interpolation (at most proximal and highest
error R0) overlayed. Top left: ∆ = 0.02cm, ν1. Top right: ∆ = 0.02cm, ν2.
Bottom left: ∆ = 0.04cm, ν1. Bottom right: ∆ = 0.04cm, ν2.
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Figure F.8: Percentage error at the point (in z) of maximum error. Top left:
∆ = 0.02cm, ν1. Top right: ∆ = 0.02cm, ν2. Bottom left: ∆ = 0.04cm, ν1.
Bottom right: ∆ = 0.04cm, ν2.
F.3. METHOD: NON-LINEAR INTERPOLATION OF THE FUNCTION
SPACE 160
proton Bragg peaks.
The absolute error of the interpolation method is shown in the figure with the
same title (figure 13.6). It is seen that with increasing R0, the accuracy of the
method improves. Further for a certain z value, the error is at a maximal peak.
We find the error is greater for increased ∆. As an idea of the percentage accuracy,
the absolute error is shown overlayed to the associated D˜ and illustrates that the
absolute error is negligibly small compared to the overall true D˜. This section also
contains an evaluation of the peaks on the graphs, showing the percentage error
at the point of maximum error decreasing with increasing R0 with the percentage
error for the ν1 for ∆ = 0.02cm at the most proximal R0 at 4.1×10−4%.
The accuracy of this method is limited by the z step sizing due to the R0 linear
interpolation before the non-linear interpolation is performed (this is performed
because we must call a line number which is always an integer). We have also
found in this method that increasing ∆ to a few cm, still achieves accuracies of
1%. Decreasing the output step size of z would therefore improve the accuracy of
the method.
Since the evaluation of R0a f(e)f(d) values requires both R01 and R02 f(e)f(d)
values (above and below), the first z that can be evaluated using this method is
∆/2. For each R0 case, this problem can be worked around by using the linear
method of interpolation at the lower end for z. However in context we believe this
problem is vanishingly small, as in practice one rarely would need accuracies for z
less than ∆/2 for each R0 because the accuracy landscape is uniformly flat across
all R0 values and there are no peaks. I would suggest therefore this is the accuracy
limit where other things become more important compared to other variables such
as accurate evaluation of the energy of the beam, etc.
F.3.4 Conclusions
From the same reasoning as with the linear method section of this appendix, it
makes sense that the accuracy of the method improves at reduced ∆ and partic-
ularly higher accuracy is found at higher values of R0. For the analytical LET
model this method is fully automated which is a great advantage over manually
computing table values for each Bragg peak separately of the overall SOBP. By
simply reducing ∆ arbitrarily, there is in principle no ceiling for how accurate this
method can be. This method has proved to be superior to the linear interpolation
method, achieving accuracies a factor of 104 better at least, at worst case scenario
for ∆ = 0.02cm, ν1 finding 4.1×10−4%. Consideration should be taken for the
limitation of the method below z = ∆/2 lower end, as discussed in this technical
note. By improving the step size of the z output for each readfile, the error on the
linear interpolation of the R0a value as shown would be reduced, further improving
the accuracy.
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F.4 Derivation of Analytical LET Units
As referenced previously (including the symbolic definition previously), the units
of dose averaged LET will be of the form:
Ld =
〈S2〉z
〈S〉z
(F.24)
LET here is in units of MeV/cm; how to convert to keV/µm:
MeV/cm = 106eV/10−2m = 108eV/m
keV/µm = 109eV/m
From inspection of the equations in this document one can find that D˜ is dimen-
sionless and so is Γ. Furthermore the exponential terms are dimensionless as well
because of the units of ζ and ξ as given in this document. Looking at the Bortfeld
formulation of σ, we find:
σ2 = α′p2α
2
p
R
3− 2
p
0
3− 2
p
=
α′p3α
2
p
3p− 2 R
3− 2
p
0
So for the units here the p term is dimensionless, and as previously we find α′ is in
MeV2/cm. For the α term, we find from the basic formulation R0 = αE
p that α
has units of cm/MeVp. Therefore inputting these results, σ2 has units of cm2 and
therefore σ has units of cm. The regularization term R has units of cm. Therefore
the term inside the brackets for the 〈S2〉 has units of cm2/p. Similarly for the 〈S〉
term, the term inside the brackets has units of cm1+1/p. When doing the division,
some of the terms cancel, leaving 1/α1/p as a pre-constant post division; this has
units of MeV/cm1/p. Therefore this is multiplied by cm2/p/cm1+1/p which gives
MeV/cm which is the desired result.
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